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INTRODUCTION: 
 
Oral administration is the most convenient and chosen means of any drug delivery 
to the systemic circulation. Oral controlled release drug delivery has been of increasing 
interest in pharmaceutical field to achieve improved therapeutic advantages, such as ease 
of dosing administration, patient compliance and flexibility in formulation. 
Drug delivery refers to approaches, formulations technologies and system for 
transporting a pharmaceutical compound in the body as need to safety achieve its desired 
therapeutic effect. 
TYPES OF DRUG DELIVERY SYSTEM: 
 
1. CONVENTATIONAL DRUG DELIVERY SYSTEM: 
 
o Oral Delivery 
o Buccal / Sublingual delivery 
o Rectal Delivery 
o Intravenous Delivery 
o Subcutaneous Delivery 
o Intra muscular Delivery etc., 
2. NOVEL DRUG DELIVERY SYSTEM: 
 
a) Targeted drug delivery 
 
o Nanoparticles 
o Niosomes 
o Microspheres 
o Monoclonal antibodies 
o Liposome’s 
o Magnetic microspheres 
o Released erythrocytes 
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b) Controlled /Sustained Release drug delivery system 
 
o Oral 
o Parenteral 
o Buccal/Sublingual 
o Rectal 
o Nasal 
o Pulmonary 
o Intrauterine / vaginal 
o Transdermal 
c) Gastro retentive drug delivery system: 
 
o Floating Drug delivery system 
o Bio / muco adhesive system 
GASTRORETENTIVE DRUR DELIVERY SYSTEMS1 
 
A controlled drug delivery system with prolonged residence time in the stomach is 
of particular interest for drug that; 
 
i. Are local active in the stomach. 
 
ii. Have an absorption window in the stomach or in the upper small intestine 
 
iii. Are unstable in the intestinal or colonic environment or 
 
iv. Exhibit low solubility at higher value. 
NEED FOR GASTRO RETENTION IN GRDDS2, 3: 
 
 Drugs that are absorbed from the proximal part of the GIT 
 Drugs that are less soluble or that degrade by the alkaline pH the encounters at the 
lower part of GIT. 
 Drugs that are absorbed due to variable gastric emptying time. 
 Local or sustained drug delivery to the stomach and proximal small intestine to 
treat certain conditions. 
 Advantageous of local action by Prolonged gastric retention time (GRT) in 
stomach e.g. Treatment of peptic ulcer, etc., 
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 Drugs with variable bioavailability. 
 Drugs with short half-life. 
 Drugs those degrade in colonic ulcers caused by H. Pylori infections13 
 
 
PHYSIOLOGICALCONSIDERATIONS1, 2 
 
 
Fig. No. 1: Anatomy of stomach 
 
Stomach Physiology2, 3: 
The stomach is categorized into 3 anatomic regions: fundus, body, and antrum 
(pylorus). The part of fundus and body turns as a reservoir for undigested material, 
whereas the antrum is the main site for mixing motions and act as a pump for gastric 
emptying by propelling actions. The separation between stomach and duodenum is the 
pylorus. The pylorus, plays a major role in gastric residence time of GRDF due to its 
size. 
The stomach provides for short term food reservation and quick consumption of 
relatively large meal. The primary substantial metabolism of enzymes is promoted in 
stomach of proteins. The peristalsis of stomach mix up and grind consumed food with 
secretions of the stomach, turning food in simplified liquid form. The liquefied bulk is 
transported to the small intestine for further digestion. 
INTRODUCTION 
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Both the fasting and fed states cause gastric emptying. However the two states 
are varied upon pattern of motility. The phenomenon, series of electric events takes 
place in cycles via stomach and intestine every 2 to 3hours. This is named as inter 
digestive mylo electric cycle or migrating mylo electric cycle (MMC), which is further 
divided into following four phases1: 
 
Different Features of Stomach: 
 
Gastric pH : Fasted healthy subject 1.1 ± 0.15 
 
Fed healthy subject 3.6 ± 0.4 
Volume : Resting volume is about 25-50 ml 
Intestinal pH : In the duodenum, the section closest to the 
pyloric sphincter of the stomach may be 
acidic (due to the HCl). However, the acidic 
chime from the stomach is quickly 
neutralized through the release of secretin 
which targets the pancreas to release an 
alkaline solution, bringing the pH back up to 
around 
Gastric secretion : Acid, pepsin, gastrin, mucus and some 
enzymes about 60ml with approximately 4ml 
of hydrogen ions per hour. 
Intestinal secretion : Pancreatic secretion: trypsin, chymotrypsin 
and carboxy Polypeptidase, pancreatic 
amylase, pancreatic lipase 
Intestinal Enzymes : Peptidase, disaccharides, intestinal lipase, 
intestinal amylase. 
Effect of food on Gastric secretion : About 3 liter of secretions are added to the 
food. 
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➢ Phase I (basal phase) 
• The quiescent period lasts from 30 to 60 min with rare contractions. 
• Is Period of contraction. 
➢ Phase II (Preburst phase) 
• Exhibits intermittent action potential for 20 to 40 min with increasing 
contractile motions. Bile enters the duodenum during this phase while the 
gastric discharge occurs during the latter part of phase II and throughout 
phase III. 
• Is Period of Intermittent Contractions. 
➢ Phase III (Burst phase) 
• It has a housekeeping role and serves to clear all indigestible materials 
from the stomach and small intestine and lasts for 10 to 20 min. 
Consequently, a controlled- release gastrointestinal drug delivery system 
must capable of resisting the action of phase III. Studied release that in 
fed state, the gastric emptying rate is slowed and the onset of MMC is 
delayed. It concluded that feeding result in a lag time before onset of 
gastric emptying rate. 
• Period of regular contraction at the maximal frequency that migrate 
distally. 
➢ Phase IV lasts for 0 to 5 min is a transition period between phase III and I of 
decreasing activity until the next cycle begins. 
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Table 1: Transit times of different dosage forms across the segments of GIT 
 
 
Dosage form 
Transit time (hours) 
Gastric Small intestine Total 
Tablets 2.7±1.5 3.1±0.4 5.8 
Pellets 1.2±1.3 3.4±1.0 4.6 
Capsules 0.8±1.2 3.2±0.8 4.0 
Solution 0.3±0.07 4.1±0.5 4.4 
 
 
pH (Hydrogen Ion Concentration) : 
 
The pH of the stomach in fasting state is ~1.5 to 2.0 and in fed state is 2.0 to 
6.0. A large volume of water administered with an oral dosage form raises the pH of 
stomach contents to 6.0 to 9.0. Stomach doesn’t get time to produce sufficient acid 
when the liquid empties the stomach. The various pH of the gastro intestinal tract is 
shown below, 
 
 
Table 2: The mean pH (+ S.D.) along the G.I. Tract in normal subjects 
 
 
 
Region Mean pH 
Stomach 1.8 + 0.6 
Proximal Small Intestine 6.6 + 0.5 
Mid Small Intestine 7.4 + 0.4 
Distal Small Intestine 7.5 + 0.5 
Right Colon 6.3 + 0.6 
Mid Colon 6.6 + 0.8 
Left Colon 7.1 + 0.7 
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FACTORS CONTROLLING GRDDS4: Factors controlling GRDDS are 
shown in Figure 2 and some of the factors are enumerated below: 
 
 
Fig. No. 2: Factors controlling GRDDS 
 
1. Density: 
 
Dosage form with lower density in the gastric content can float to the surface 
while high density sink to the bottom of the stomach. Suitable density required for 
floating property is less than 1.0 gm/ cm3 
2. Size: 
 
Size should be more than 7.5 mm in diameter. 
 
3. Shape: 
 
Either round or spherical shaped dosage form exhibit better property related to 
other shapes. 
4. Single or multiple unit formulation: 
 
Multiple units are desirable due to foretell release profile. 
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5. Fed or Unfed State: Gastric retention time is less during fasting condition due to 
rise in gastric motility. 
6. Nature of Meal: 
 
High amount of fatty acid and other indigestible polymers slow down the gastric 
retention time due to variation in gastric motility 
7. Frequency of Feed: 
 
Low frequency of migrating myoelectric complex (MMC) contributes to GRT up 
to 400 times which in turn depends on the frequency of food intake 
8. Caloric Content: 
 
A high protein and fat rich diet can increase GRT by 4 to 10h. 
 
9. Gender: 
 
Males have greater GRT than females 
 
10. Age: 
 
GRT is more in geriatric patients and less in neonates and children. Age above 70 
(>70) exhibit longer GRT. 
11. Disease State: 
 
Gastric disease such as diabetes, Chron’s disease, hypothyroidism, 
hyperthyroidism, duodenal ulcers etc fluctuates the GRT 
12. Concomitant Intake of Drug: 
 
Combination of some drugs along with gastric motility enhancers or depressants, 
affect GRT. 
13. Posture: 
 
Floating can vary between supine and upright ambulatory states of the patient. 
Supine position offers no reliable protection against early and erratic emptying. 
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APPROACHES TO GASTRICRETENTION 5 
To enhance the gastro retention of the orally administered drugs by 
different approaches which including floating and non-floating systems 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Matrix 
tablets 
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with ion exchange 
 
 
 
 
 
Fig.No. 3: Approaches to gastric retention drug delivery system 
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I. FLOATING DRUG DELIVERY SYSTEMS 
The concept of FDDS was described in the literature as early as. FDDS have a 
bulk density less than gastric fluids and so remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolonged period of time. While the system is 
floating on the gastric contents the drug is released slowly at the desired rate from the 
system. This results in an increased GRT and a better control of fluctuations in plasma 
drug concentration. 
 
a=swelling system  b=force of gravity c=gas generating system 
Fig.No.4: Mechanism of floating system 
Mechanism of action involves in floating drug delivery systems6 
Floating system on the gastric, the drug are released slowly at the desired rate 
from the system. After release of drug, the residual system are emptied from the stomach 
besides a minimal gastric content needed to allow the proper achievement of the 
buoyancy retention principle, a minimal level of floating force (F) is also required to keep 
the dosage form dependably buoyant on the surface of the meal18. 
F=F buoyancy – F gravity 
F= (DF-Ds) g 
Where, 
F=total vertical force, 
DF= fluid density, 
Ds = object density, 
v = volume and 
g = acceleration due to gravity. 
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Diffusion: 
On contact with aqueous fluids in the gastrointestinal tract (GIT), water diffuses 
into the interior of the particles. Drug dissolution occurs and the drug solutions diffuse 
across the release coat to the exterior. 
Erosion: 
Some coatings can be designed to erode gradually with time, thereby releasing the 
drug contained within the particles. 
Osmosis: 
In allowing water to enter under the right circumstances, an osmotic pressure can 
be built up within the interior of the particle. The drug is forced out of the particle into the 
exterior through the coating18. 
TYPES OF FLOATING DRUG DELIVERY SYSTEMS 
Based on the mechanism of buoyancy and two distinctly different technologies 
have been utilized in the development of FDDS. 
I. Effervescent Floating Drug Delivery System 
 
II. Non- Effervescent Floating Drug Delivery System 
 
I.1. EFFERVESCENT FLOATINGDRUG DELIVERY SYSTEM1, 7: 
 
Floating systems come under low density approach. In this approach, the density of 
pellets should be less than 1 g/ml, so as to float the pellets or tablets in the gastric fluid 
and, release the drug slowly for a longer period of time. 
I.1.1. Volatile liquid / vacuum containing systems: 
 
i. Intra-gastric floating gastrointestinal drug delivery system: 
These systems can be made to float in the stomach because of floatation 
chamber, which may have a vacuum or filled with air or an harmless gas, while 
drug reservoir is encapsulated inside a micro-porous compartment. 
Fig.No 5: Intra gastric floating gastrointestinal drug delivery device 
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ii. Inflatable gastrointestinal delivery systems 
 
These systems are fabricated by loading the inflatable chamber with a drug 
reservoir, which can be a drug impregnated polymeric matrix. It automatically 
inflates and retains the drug reservoir compartment in the stomach. The drug is 
continuously released from the reservoir into the gastric fluid (Figure). 
Fig.No. 6: Inflatable gastrointestinal delivery system 
 
iii. Intragastric osmotically controlled drug delivery system 
The osmotic pressure controlled drug delivery device consists of two 
components; drug reservoir compartment and an osmotically active compartment. 
The drug reservoir compartment is enclosed by a pressure responsive collapsible bag, 
which is impermeable to vapors and liquid and has a drug delivery orifice. It contains 
an osmotically active salt and is enclosed within a semi-permeable housing. The 
osmotic pressure thus created acts on the collapsible bag and in turn forces the drug 
reservoir compartment to reduce its volume and activate drug release through the 
delivery orifice. 
 
 
 
 
 
I.1.2Matrix Tablets: 
Fig.No. 7: Intragastric osmotically controlled drug 
delivery system. 
 
They are formed by intimate mixing of drug with a gel forming hydrocolloid, which 
swells in contact with gastric fluid and maintain bulk density of less than unity. The air 
trapped by the swollen polymer confers buoyancy to these dosage forms. 
INTRODUCTION 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 13 
 
 
 
I.2. NON-EFFERVESCENTFLOATING DRUG DELIVERY SYSTEM1, 8: 
Non-effervescent floating dosage forms use a gel forming or swellable cellulose 
type of hydrocolloids, polysaccharides, and matrix forming polymers like polycarbonate, 
polyacrylate, polymethacrylate, and polystyrene. The formulation method includes a 
simple approach of thoroughly mixing the drug and the gel-forming hydrocolloid. After 
oral administration this dosage form swells in contact with gastric fluids and attains a bulk 
density of < 1. 
I.2.1. HYDRODYNAMICALLY BALANCED SYSTEMS: 
 
These are single-unit dosage forms, containing one or more gel-forming 
hydrophilic polymers. Hydroxy propyl methyl cellulose (HPMC) is the most 
commonly used excipient. Drug release is controlled by the formation of a hydrated 
boundary at the surface. Continuous erosion of the surface allows water penetration to 
the inner layers, maintaining surface hydration and buoyancy (Figure). 
 
 
Fig. No. 8: Working Principle of Non-Effervescent type 
(HBS-Hydro dynamically balanced system) of FDDS 
 
 
I.2.2. HOLLOW MICROSPHERES: 
 
Multiple-unit microspheres by emulsion solvent diffusion technique were prepared with 
drug and acrylic polymer. These were dissolved in an ethanol- dichloromethane mixture, 
and poured into an aqueous solution of PVA with stirring to form emulsion droplets. The 
rate of drug release in micro balloons was controlled by changing the polymer to drug ratio. 
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Fig .No.9: Hallow microspherses 
 
I.2.3. ALGINATE BEADS: 
 
Multi-unit floating dosage forms were developed from freeze dried 
calcium alginate. Spherical beads of approximately 2.5mm diameter can be 
prepared by dropping sodium alginate into aqueous solution of calcium chloride, 
causing precipitation of calcium alginate leading to formation of porous system, 
which can maintain a floating force for over 12 hour. These floating beads gave a 
prolonged residence time of more than 5.5 hour 
I.2.4. LAYERED TABLETS: 
 
It can be formulated in a single layer matrix table by implementing 
bicarbonates in the matrix forming hydrocolloid gel agent or in a dual layer matrix 
along with gas generating matrix together as an individual layer. The drug acts as 
the second layer. There is a possibility of triple layer matrix tablet. However now 
the gas generating matrix is one layer and rest two are drug layers. 
 
 
II. NON-FLOATING SYSTEM: 
 
 
Fig.No.10: GRDDS based on high density. 
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II.1. BIO/MUCO-ADHESIVE SYSTEMS 9 
Bio/muco-adhesive systems, bind to the gastric epithelial cell surface or mucin, 
which extends the GRT of drug delivery system in the stomach. The ability to provide 
adhesion of a drug delivery system to the gastrointestinal wall provides longer 
residence time in a particular organ site, it improved effect in terms of local action or 
systemic effect. Binding of polymers to the mucin/epithelial surface can be divided into 
three categories: 
(i) Hydration-mediated adhesion: 
Certain hydrophilic polymers tend to imbibe large amount of water and become 
sticky, thereby acquiring bio adhesive properties. 
(ii) Bonding-mediated adhesion: 
It include physical-mechanical bonding and chemical bonding. Physical- 
mechanical bonding can result from the insertion of the adhesive material into the 
folds or crevices of the mucosa. Chemical bonds may be either covalent (primary) 
or ionic (secondary) in nature. Secondary chemical bonds consist of dispersive 
interactions (i.e., Vander Waals interactions) and stronger specific interactions 
such as, hydrogen bonds. 
(iii) Receptor-mediated adhesion: 
Certain polymers bind to specific receptor sites on the cell surfaces, thereby 
enhancing the gastric retention of dosage forms. Various investigators have 
proposed different mucin-polymer interactions, 45 such as: 
 Wetting and swelling of the polymer to permit intimate contact with the 
biological tissue. 
 Formations of weak chemical bonds. 
 Sufficient polymer is mobility to allow spreading. 
 Water transport followed by mucosal dehydration. 
 
 
Fig.No.11: GRDDS based on muco-adhesive systems 
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II.2. MAGNETIC SYSTEMS: 
 
The incentives from external is used as magnetic field in these systems  for 
targeted drug delivery, the compound that are active magnetically are added in these 
systems to attain the targeted drug delivery. 
 
Fig.No.12: GRRDS based on application of magnetic force 
II.3. High density systems: 
 
In these systems the pallets are coated, having the greater density than the contents 
of the stomach (1.004 gm/cm3). The preparation of these type of tablet is done on the 
basis of high-density tablet is based on hypothesis that dense pellets will stay in stomach 
for longer time. Such polymers are, Zinc oxide, Barium Sulphate, Iron powder, 
Titanium dioxide. 
II.4. Swelling type system: 
 
In these systems contain the ingredients those have swelling property and 
they swell to that extent, so they cannot pass out from stomach through pylorus. The 
name “Plug type system”, can also be given to them, so they are logged in pyloric 
sphincters for greater time. such polymers are, Biodegradable polymers are used, 
Swelling agents (cross povidone, sodium starch glycolate) 
 
Fig.No.13: Swellable systems, developed by (a) Mamajek and (b) Moyer 
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II.5. Raft forming System: 
Incorporate alginate gel-these have carbonate component and upon reaction with 
gastric acid, bubbles form in the gel, enabling floating. 
Fig.No.14: Schematic illustration of the 
barrier formed by a raft-forming system 
CRITERIA FOR SELECTION OF DRUG CANDIDATE FOR FDDS 
Desirable half-life: 
If the drug has a short half-life of less than 2 hours, the dosage form may contain a 
prohibitively large quantity of the drug. 
High therapeutic index: 
Drugs with low therapeutic index are not suitable for incorporation in controlled 
release formulations. 
Small dose: 
The dose of a drug in the conventional dosage form is high, its suitability as a 
candidate for controlled release is seriously undermined 
Aqueous solubility: 
Drugs with aqueous solubility make good candidates for controlled release dosage 
form. 
Stability to wide pH range, GI enzymes and flora: 
Stability of the drug in the GI contents is important to ensure a complete and 
reproducible drug input into the body. Typically the drug must be stable in the pH range of 
1 to 8. 
First pass clearance: 
Delivery of the drug to the body in desired concentration is seriously hampered in 
case of drugs undergoing extensive hepatic first pass metabolism, when administered in 
controlled release form. Saturable hepatic metabolism may render a drug unsuitable 
because systemic availability for such drug is highly reduced when the input rate is 
small20 
INTRODUCTION 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 18 
 
 
 
Table 3: Marketed Products of GRDDS11 
 
 
Brand 
name 
Delivery system Drug (dose) Company name 
Almagate 
Flot-Coat® 
Antacid tablet 
preparation 
Al – Mg antacid Roche, USA 
Topalkan® Floating liquid 
alginate 
Preparation 
Al – Mg antacid Pierre Fabre Drug, 
France 
Valrelease® Floating capsule Diazepam (15mg) Hoffmann- 
LaRoche, USA 
Madopar® 
HBS 
(Prolopa® 
HBS) 
Floating, CR capsule Benserazide 
(25mg) and L- 
Dopa (100mg) 
Roche Products, 
USA 
Liquid 
Gaviscon® 
Effervescent Floating 
liquid alginate 
preparations 
Al hydroxide (95 
mg), 
Mg Carbonate 
(358 mg) 
GlaxoSmithKline, 
India 
Conviron® Colloidal gel forming 
 
FDDS 
Ferrous sulphate Ranbaxy, India 
Cytotech® Bilayer floating 
capsule 
Misoprostol 
 
(100µg/200µg) 
Pharmacia, USA 
INTRODUCTION 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 19 
 
 
 
ADVANTAGES OF GASTRORETENTIVE DRUG DELIVERY SYSTEM12: 
1. Improves patient compliance e.g. Furosemide 
2. Enhanced bioavailability. 
3. Increased Gastric retention time. 
4. Enhanced absorption of drugs which is solubilize only in stomach. 
5. Drug releases in controlled manner for prolonged period. 
6. To Site-specific drug delivery to stomach can be achieved. 
7. Superior to single unit floating dosage form - no risk of dose dumping. 
8. Avoids gastric irritation in stomach. 
9. Better therapeutic effect of short half-life drugs can be achieved. 
 
 
DISADVANTAGES OF GRDDS 13 
 
1. Need for increased level of fluids in the stomach. 
2. Unsuitable for such drugs as: 
 Problematic with solubility in gastric fluid 
 Causing G.I irritation 
 Inefficient in acidic environment 
 
3. Drugs intended for selective release in the colon. 
4. Unpredictable adherence owing to state of constant renewal of mucus wall of 
stomach. 
5. GRDDS is fed into the system after the meal as time of stay in stomach 
depends on digestive state. 
6. The ability of the drug to remain in the stomach depends upon the subject being 
positioned upright. 
7. Hydrogel based swelling system takes longer time to swell. 
8. Gastric emptying of floating forms in supine subject may occur at random ad 
becomes highly on the diameter size. Therefore patients should not be dosed 
with forms just before going to bed. 
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Limitations of the Techniques of Gastro/Intestinal retention14 
 
 The adequate amount of the fluid must be present in the stomach, for the 
administration of the floating dosage forms requires normally 200-250ml fluid 
in the stomach 10, to retain the buoyancy outcome effect of the formulation 
 Not suitable for drugs that may cause gastric lesions e.g. Non-steroidal anti-
inflammatory drugs. 
 Drugs degraded by first pass effect and have good absorption in the whole 
gastric tract are not right choice for the floating drug delivery system due to 
their ability to reduce the gastric emptying that in turn reduce  the 
bioavailability systematically. 
 More predictable and reproducible floating properties should be achieved in all 
the extreme gastric conditions 
 For Intestinal retention, dosage form has to cross gastric conditions intact, 
which is not easily achievable. 
 Not suitable for drugs that are unstable in the strong acidic or basic 
environment. 
 These systems do not offer significant advantages over the conventional dosage 
forms for drugs that are absorbed throughout the gastro intestinal tract. 
 
 
POLYMERS AND OTHER INGREDIENTS USED IN GRDDS TABLETS15: 
 
Following types of ingredients can be incorporated into HBS dosage form in 
addition to the drugs: 
1. Hydrocolloids (20%-75%): 
 
They can be synthetics, anionic or non-ionic like hydrophilic gums, modified 
cellulose derivatives. 
E.g. Acacia, pectin, Chitosan, agar, casein, bentonite, Veegum, HPMC (K4M, 
K100M and K15M), Gellan Gum (Gel rite®), Sodium CMC, MC, HPC. 
2. Inert fatty materials (5%-75%): 
 
Edible, inert fatty materials having a specific gravity of less than one can be used 
to decrease the hydrophilic property of formulation and hence increase buoyancy. E.g. 
Beeswax, fatty acids, long chain fatty alcohols, Gelucires® 39/01 and 43/01. 
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3. Effervescent agents: 
 
E.g. Sodium bicarbonate, citric acid, tartaric acid, Di- SGC, CG 
 
4. Release rate accelerants (5%-60%): 
 
E.g. lactose, mannitol 
 
5. Release rate retardants (5%-60%): 
 
E.g. Dicalcium phosphate, talc, magnesium stearate 
 
6. Buoyancy increasing agents (upto80%): 
 
E.g. Ethyl cellulose, Polysaccharides. 
 
7. Low density material: 
 
E.g. Polypropylene foam powder. 
 
EVALUATION PARAMETERS FLOATING DRUG DELIVERY SYSTEM1, 16 
 
i) Floating time: 
 
The test for floating time is usually prepared in simulated gastric fluid or 0.1 
mole .lit-1 HCl maintained at 37⁰C, by using USP dissolution apparatus containing 
900ml of 0.1 molar HCl as the dissolution medium. The time taken by the dosage form 
to float is termed as floating lag time and the time for which the dosage form floats is 
termed as the floating or floatation time. 
ii) Drug release: 
 
Dissolution tests are performed using the dissolution apparatus. Samples are 
withdrawn periodically from the dissolution medium with replacement and then 
analyzed for their drug content after an appropriate dilution. 
iii) Measurement of buoyancy capabilities of the FDDS 
 
The floating behavior was evaluated with resultant weight measurement. The 
experiment was carried out in two different media like deionized water and simulated 
meal, in order to monitor possible difference. The results showed that higher molecular 
weight polymers with slow rate of hydration had enhanced floating behavior and which 
was more in simulated meal medium compared to deionized water. 
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iv) Content uniformity, Hardness, Friability (Tablets): 
 
These test are performed as per described in specified monographs. 
 
Resultant weight: The in vitro measuring apparatus has been conceived to determine 
the real floating capabilities of buoyant dosage form as a function of time. It operates 
by force equivalent to the force F required to keep the object totally submerged in the 
fluid. This force determine the resultants weight of the object when immersed and  
may be used to quantify its floating or non-floating capabilities. The magnitude and 
direction of the force and the resultant weight corresponds to the Victoria sum of 
buoyancy (F buoy) and gravity (F grav) forces acting on the objects as shown in the 
equal. In which the F is total vertical force (resultant weight of the object). G is the 
acceleration due to gravity, df if the fluid density, ds is the object mass and V is the 
volume of the object. 
v) X-Ray /Gamma scintigraphy: 
 
X-Ray /Gamma scintigraphy is a popularly used evaluation parameter for 
floating dosage form these days. It helps to locate dosage form in the GIT and by 
which one can predict and correlate the emptying time and the passage of dosage form 
in the GIT. Here the inclusion of a ratio –opaque material into a solid dosage form 
enables it to be visualized by X-rays. Similarly, the inclusion of a γ-emitting ratio 
nuclide in a formulation allows indirect external observation using γ-camera or scinti 
scanner. 
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REVIEW OF LITERATURE 
 
Ramu Bandameedi et al., 201517 Developed floating osmotic tablets of Nizatidine, a 
H2 receptor antagonist, to release the drug as two distinct pulses separated by a lag time 
that achieve plasma concentration profiles varying in a circadian rhythm fashion, for 
the chronotherapy of ulcer. Floating osmotic tablets were developed using 
effervescence method consisted of three different steps viz, preparation of floating 
sustained release drug containing tablets followed by time-lagged (4 hrs) coating with 
hydrophobic rupturable polymer, ethyl cellulose (EC), and finally compression coating 
with immediate release dose of Nizatidine and supporting buoyant layer. Three ratios of 
Ethyl cellulose to HPMC E15 (32.5:67.5, 50:50, and 67.5:32.5) at three coating levels 
(5%, 10%, 15%) were used to optimize the lag time (4 hrs). Carbopol 934P, cross 
povidone and sodium bicarbonate were used in buoyant layer. The developed floating 
osmotic tablets by effervescence method were evaluated for preformulation parameters, 
weight variation, thickness, hardness, friability, drug content, content uniformity, In-
vitro floating properties, and In-vitro drug release. The optimized formulation provided 
expected two-phase release pattern of Nizatidine with initial immediate dose release in 
30 min and then lag time 4 hrs of no drug release followed by sustained release for 8hrs 
in stomach during floating. 
 
Chouresoniyaet al.,  201518 Studied the floating tablet of Nizatidine using the 
hydrophilic polymer hydroxypropyl and gas generating agent sodium bicarbonate and 
citric acid by wet granulation method . Nizatidine is H2 receptor antagonist and anti-
ulcer having dose 150mg twice daily. The drug excipients compatibility studies were 
conducted by using FTIR, DSC and visual observations. The granules were prepared 
by wet granulation method and evaluated for their granules properties. A 32factorial 
design was applied to systemically optimize the drug release profile. The amount of 
citric acid (X1) and concentration of polymer HPMC K100M (X2) were selected as 
independent variables. The % drug release at 6 hour (Q6) and drug release at 12 hour 
(Q12), and t50 % were selected as dependent variables. The results of factorial design 
indicated that low level of HPMC K100M favours the preparation of floating 
controlled release of Nizatidine tablets. Effect of hardness on floating tablet revealed 
that increase in hardness affect buoyancy lag time due to reduction in porosity of 
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compact mass. Formulations of NFT 7 provided sustained release of Nizatidine over 
the period of 12 hrs. 
Rushikesh K, et al.,201419 Nizatidine floating tablets was prepared using different 
grades of HPMC as drug release retarding polymer and sodium bicarbonate as source 
for carbon dioxide which helps tablets to float. Floating drug delivery system (FDDS) 
was developed using gas sodium bicarbonate, citric acid and hydrocolloids, 
hydroxypropyl methylcellulose (HPMC) and Carbopol 940P. The prepared tablets 
were evaluated their physicochemical properties and drug release, excipient 
compatibility, density, buoyancy test, mucoadhesion force, swelling study, drug 
content and vitro release profile. 
Xuehua Zhu et al., 201420Studied famotidine-containing floating-bio adhesive 
cooperative minitablets and investigated the possibility of using those minitablets as a 
delivery system for promoting the oral bioavailability of famotidine. Nine minitablet 
formulations were designed using hydroxylpropyl methylcellulose (HPMC K4M) as 
release retarding polymers, Carbopol 971P as bio adhesive materials and sodium 
bicarbonate (NaHCO3) as gas formers. The prepared 3 ± 0.02 mm minitablets were 
evaluated in terms of their swelling ability, floating behaviour, bio adhesion test and in 
vitro release. The optimized minitablets (F6) containing HPMC K4M (50.00%, w/w), 
Carbopol 971P (10.00%, w/w) and NaHCO3 (10.00%, w/w) were found to float in 1 
min and remain lastingly buoyant over a period of 8 h in vitro, with excellent bio 
adhesive properties (20.81 g) and sustained drug release characteristics (T50% ¼ 
46.54%) followed one-order model. In addition, plasma concentration–time profiles 
from pharmacokinetic studies in rats dosed with minitablets showed 1.62-fold (p50.05) 
increased absorption of Famotidine, compared to the market tablets Xin Fading. These 
studies demonstrated that the multiple-unit floating-bio adhesive cooperative 
minitablets may be a promising gastro-retentive delivery system for drugs that play a 
therapeutic role in the stomach. 
Gehan Balata et al.,201421 Formulated a gastroretentive floating tablet of Nizatidine 
by direct compression technique using hydroxylpropyl methylcellulose (HPMC k4M). 
The effect of different formulation variables including polymer concentration, 
incorporation of different concentrations of carbopol934 or sodium alginate as release 
retarding polymers and concentration of an effervescent mixture (sodium bicarbonate 
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and citric acid) on drug release and floating properties was investigated. In addition, 
the optimized formulation (combined excellent floating behaviour and sustained drug 
release) was compared to conventional Nizatidine tablet for antiulcer activity in 
rabbits. The optimized formulation containing 175 mg HPMC k4M, 25 mg 
carbopol934 and 50 mg effervescent mixture showed 80% drug release within 10.6 
h±0.3, floating lag time of about 5.00±0.2 min and total floating time of >24 hours. In 
vivo results proved that Nizatidine floating tablet had more pronounced antiulcer 
effect than its conventional tablet. The effervescent based floating tablet of Nizatidine 
could be a promising approach to increase its gastric residence time up to 12 hours, 
thereby improving its antiulcer efficacy. 
Pawan Jalwal, Anupama Diwan22et al., 2013Formulated a sustained drug delivery of 
famotidine is histamine H2 receptor antagonist in treating gastric ulcer, duodenal ulcer, 
Zollinger Ellison syndrome, gastro oesophageal reflux disease and erosive esophagitis 
but their main clinical use is as inhibition of gastric acid secretion. It inhibited 
histamine stimulation and gastrin stimulated acid secretion. It decreases both basal and 
food stimulated acid secretion by 90% or more, but promote healing of duodenal ulcer. 
The swelling of the polymers used (HPMC K15M, Ethyl cellulose, Xanthan Gum) were 
determined by water uptake of the tablet. The percent swelling of the tablet was 
determined for 12 h at different time intervals. Increase in percent swelling was found 
with increasing concentration of polymers. 
 
 
Ashish Kumar Garg,et al., 201223 Formulated  a floating drug delivery system of an 
antiulcer drug Nizatidine using different grades of HPMC (K100, K4M, K15M & 
K100M) and an effervescent agent i.e. sodium bicarbonate. It was found that the 
release rate of Nizatidine from tablet formulations prepared from HPMC K100LV was 
very high as compared to that from formulations containing higher viscosity grades 
namely K4M, K15M and K100M. In the current study, it was also found that overall 
rate of drug release tends to decrease with increase in concentration of HPMC. These 
observations are in agreement with the results reported in literature i.e. with the 
increase in polymer concentration and viscosity grade, the viscosity of gel layer 
around the tablet also increases leading to enhanced diffusional path length for the 
drug to follow and thus limits the release of active ingredient. 
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A Sarat Chandra et al., 201224Developed a floating gastro retentive dosage of 
Nizatidine using effervescent technique. Nizatidine was used as a model drug because 
of its short elimination half-life and localized action in the gastric region. Nine batches 
containing 75mg of Nizatidine per tablet were developed using release modifiers like 
xanthan gum and HPMC K100M both individually and in 1:1 combination at 30, 40 
and 50% concentrations. Sodium bicarbonate and tartaric acid were used as gas 
generating agents. The drug-excipient compatibility, pre and post compression 
parameters, buoyancy properties and swelling index were evaluated. In-vitro 
dissolution studies were carried out in 0.1N HCl (pH 1.2) at 37±0.5oC. Increase in 
polymer concentration showed significant retardation of drug release and increase in 
swelling property. Release kinetics were studied by fitting the data into various models 
and release mechanism, predicted drug release were studied. Best formulation among 
the designed batches was selected based on cumulative percentage of drug released by 
the end of twelfth hour and by comparing the predicted and obtained drug releases at 
the end of 5th and 8th hours respectively. 
 
D. Lohithasuet al., 201425Studied the Lafutidine for the effect of guar gum is an 
efficient matrix forming agent in floating tablets by generating gas Lafutidine release 
was diffusion controlled and follows zero order kinetics. In case of F3 formulation non-
Fickian diffusion was the drug release mechanism from the prepared Lafutidine floating 
tablets. Floating tablets containing 10 mg of Lafutidine could be prepared by wet-
granulation technique employing guar gum of different grades as floating polymer and 
release retardant, methocel K100LVCR, methocel K15M as floating enhancers and 
sodium bicarbonate as a gas generating agent. The measured tapped density was 0.501 
to 0.643(g/cm3), bulk density 0.421 to 0.540 (g/cm3), Carr’s index(I) 10.88 to 23.04%, 
thickness 4.33 to 4.38(mm), hardness 4.26 to 5.06 (Kg/cm2), friability 0.24 to 0.46(%) 
were well within the limits, which indicates good flow potential of the prepared tablets. 
Angle of repose (θ) values for the granules was in the range 24.19 to 26.950 indicating 
good flow potential for the tablets and the tablets with guar gum were able to float for 
more than 12 h.  
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Satish Patilet al., 201526Studied the effect of Lafutidine a newly developed histamine 
H2-receptor antagonist having biological half-life of1.92 ± 0.94 h due to its selective 
absorption from upper part of gastrointestinal tract the development of mucoadhesive 
sustained release drug delivery system is recommended inorder to enhance the 
bioavailability. The tablets was developed using the natural polymer, sodium alginate, 
xanthan gum and karaya gum. The formulation with xanthan gum showed better 
results. Thus, it may be useful for prolonged drug release in stomach to improve the 
bioavailability and reduced dosing frequency. Non-fickians release transport was 
confirmed as the drug release mechanism from the optimized formulation by 
Korsmeyer–Peppas. The optimized formulation (B3) showed a mucoadhesive strength 
435 g. In vivo study was performed using rabbits by X-ray imaging technique. 
Radiological evidences suggest that, a formulated tablet was well adhered for 410 h in 
rabbit’s stomach. Optimized Lafutidine tablet in vitro dissolution pattern showed, after 
storage part 40  ͦC temperature75 ± 5% relative humidity for 3 months. 
 
C. V. S. Raghu Kiranet al.,201527 Developed floating tablets of Lafutidine in order to 
achieve an extended retention in the upper GIT which may enhance the absorption and 
improve the bioavailability. The tablets were prepared by gas generation technique 
using different ratio and concentrations of natural gums like guar gum, gum karaya, 
hupu gum. Lafutidine a newly developed histamine H2-receptor antagonist. The 
formulation code F10 showed superior results it may be constructive for prolonged 
drug release in the stomach to get better the bioavailability and abridged the dose 
frequency. Optimized floating tablets showed no significant changes in the physical 
appearance, drug content, total buoyancy time, and also in vitro dissolution pattern after 
storage at 40°C/75% relative humidity for 3 months. 
Vageesh N.M et al., 201728Formulated the Lafutidine by using various polymers were 
developed. Initially analytical method development was done for the drug molecule. 
Absorption maxima was determined based on that calibration curve was developed by 
using different concentrations. Gas generating agent sodium bicarbonate concentration 
was optimised. Then the formulation was developed by using different concentrations 
of polymers Xanthan gum, guar gum and Sodium Alginate as polymeric substances. 
Among all the formulations Only Xanthan gum, Sodium Alginate highest 
LITERATURE REVIEW 
 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore  Page 28 
 
concentrations (60 mg) retards the drug release up to 12 hours and the drug release 
96.25%, 95.81% respectively. In this Xanthan gum releases the more drug release when 
compared to Sodium alginate. So F3 Formulation considered as optimised formulation. 
Optimised formulation F3 was kept for release kinetic studies. In the graphs it was 
evident that the formulation F3 was followed the Peppas release mechanism. 
Kapoor D et al., 201429 Prepared Lafutidine tablet in gas generation technique using 
different ratio and concentrations of Methocel K 100, Methocel K 15. Polymer with 
lower viscosity was found to be beneficial than higher viscosity polymer in improving 
the release properties of gastroretentive FDDS. The formulation code LFT6 having 
Methocel K15 showed superior results it may be constructive for prolonged drug 
release in the stomach to get better the bioavailability and abridged the dose frequency. 
In-vitro floatability studies revealed that most of the tablets still floated for more than 9 
hours because of their low densities. Lessen in the citric acid level increased the 
floating lag time but tablets floated for longer duration. An amalgamation of sodium 
bicarbonate (70mg) and citric acid (20mg) was found to achieve optimum in vitro 
buoyancy. Optimized floating tablets showed no significant changes in the physical 
appearance, drug content, total buoyancy time, and also in vitro dissolution pattern after 
storage at 40°C/75% relative humidity for 3 months. 
 
Mahboubeh Razavietal., 201430formulatedthe gastroretentive dosage form of 
famotidine was modified using tamarind seed powders to prolong the gastric retention 
time. Tamarind seeds were used in two different forms having different swelling and 
gelling properties: with husk (TSP) or without husk (TKP). TKP (TKP1 to TKP 6) and 
TSP (TSP1 to TSP 6) series were prepared using tamarind powder: xanthan in the ratios 
of 5:0, 4:1, 3:2, 2:3, 1:4, 0:5, respectively. The matrix tablets were prepared by the wet 
granulation method and evaluated for pharmacopoeial requirements. TKP2 was the 
optimum formulation as it had a short floating lag time (FLT < 30 s) and more than 
98.5% drug release in 12 h. The dissolution data were fitted to popular mathematical 
models to assess the mechanism of drug release, and the optimum formulation showed 
a predominant first order release and diffusion mechanism. It was concluded that the 
TKP2 prepared using tamarind kernel powder: xanthan (4:1) was the optimum 
formulation with shortest floating lag time and more than 90% release in the 
determined period of time. 
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Amit Kumar Nayaket al., 201731 studied various plant polysaccharides have been for 
their diverse applications as excipients like binders, granulating agents, disintegrants, 
emulsifiers, suspending agents, gelling agents, mucoadhesive agents, matrix-formers, 
release retardants, enteric resistant’s, etc., in various pharmaceutical dosage forms. 
Among these, tamarind seed polysaccharide is an emerging excipient, which is be 
ingested and investigated for the preparation of various dosage forms like suspensions, 
emulsions, tablets, gels, creams, beads, spheroids, microparticles, nanoparticles, 
ophthalmic preparations, and buccal patches, etc. The current chapter deals with a 
comprehensive and useful discussion on pharmaceutical applications of tamarind seed 
polysaccharide with its some important features like source, isolation, chemical 
composition and properties. 
 
Ruchira Vasant Mahavarkar et al., 201632formulated the matrix tablet of Diclofenac 
sodium using natural polymer was to modify the release rate. The matrix forming agent 
like Tamarind seed Polysaccharide show sustained release property in tablet which is 
obtained naturally from fruit of TamarindusindicaL. belonging to Family Leguminosae. 
The sustained release matrix tablet of Diclofenac sodium were prepared by wet 
granulation technique using varying concentration of hydrophilic polymer i.e. TSP.  
OF1 and OF2 both are optimized batch. The in vitro dissolution study was carried out 
for optimized as well as marketed formulation (Voveran- SR). Both the optimized 
batches at 10 h were found to be 90.27% and 90.18%, respectively. Tamarind seed 
polysaccharide can be employed in dosage form to sustain the drug release. Tablet 
formulated with various concentrations of Tamarind seed polysaccharide (TSP) gives 
release up to 10 h and more. OF1 and OF2 both formulations give comparable release 
with marketed formulation. From the present work it can be conclude that, the 
objectives which were set at the beginning of the study got fulfilled. 
Kesarla RS et al., 201533developed a sustained dosage form of Ranitidine 
hydrochloride (HCl) does not prevent frequent administration due to its degradation in 
colonic media and limited absorption in the upper part of GIT. FT-IR and DSC 
indicated no significant incompatibility with selected excipients Klucel-LF, POLYOX 
WSR N 60 K and l-menthol were selected as binder, Polymer and sublimating material, 
respectively, for factorial design batches after preliminary screening. From the factorial 
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design batches, optimum concentration to release the drug within 12 h was found to be 
420 mg of POLYOX and 40 mg of l-menthol. Stability studies indicated the 
formulation as stable. Ranitidine HCl matrix floating tablets were formulated to release 
90%of drug in stomach within12 h. 
Gharti K et al., 201234developed floating tablets of ranitidine using hydroxypropyl 
methyl cellulose (HPMC) and polyethylene oxide (PEO). The floating tablets were 
based on effervescent approach using sodium bicarbonate a gas generating agent. The 
tablets were prepared by dry granulation method. The result of in vitro dissolution 
study showed that the drug release profile could be sustained by increasing the 
concentration of HPMC K15 MCR and Polyox WSR303. The formulation containing 
HPMC K15 MCR and Polyox WSR303 at the concentration of 13.88% showed 91.2% 
drug release at the end of 24 hours. Changing the viscosity grade of HPMC from 
K15MCR to K100MCR had no significant effect on drug release profile. Sodium 
bicarbonate and stearic acid in combination showed no significant effect on drug 
release profile. The formulations containing sodium bicarbonate 20 mg per tablet 
showed desired buoyancy (floating lag time of about 2 minutes and total floating time 
of >24 hours). The study showed that polymers like HPMC K15MCR and Polyox 
WSR303 in combination with sodium bicarbonate as a gas generating agent can be used 
to develop sustained release floating tablets of Ranitidine hydrochloride. 
Khanittha Chawananorasest et al., (2016)35investigated the physical and chemical 
properties of Tamarind Seed polysaccharide (TSP) from tamarind seed with two 
methods and characterized. Kernel powder of tamarind seeds was slurred into a clear 
solution, set aside overnight and then centrifuged at 6000 rpm for 20 min to separate all 
foreign matter. The supernatant was separated and poured into excess 95% ethanol with 
continuous stirring. The precipitate obtained was collected and dried in the oven and 
then the dried TSP polymer was stored in a desiccator. The dried TSP was analysed 
by 1H-NMR, FT-IR and XRD. The results showed TSP from tamarind seeds taken from 
paddy farmland (A), a waste from the export tamarind juice industry (B) and the export 
tamarind powder industry(C) gave yields of 31.55%, 26.95% and 17.30%, respectively, 
using method 1 and 11.15%, 53.65% and 54.65%, with method 2, respectively, but 
method 2 gave purer TSP than method 1. The FT-IR spectra displayed peaks at 3351.95 
cm−1, 2920.76 cm−1, 1018.85 cm−1 and 555.16 cm−1. The 1H-NMR showed 
polysaccharide peaks between δ 3.50–4.20 ppm and XRD diagrams indicated their 
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amorphous nature. Future works will focus on the quantitative analysis, biological 
activity and possible use of TSP as a drug delivery system.  
Mahammed Raja. et al., (2016)36formulated and evaluated hydrodynamically balanced 
tablets of Ranitidine hydrochloride by direct compression technique with different 
ratios of polymers like hydroxyproylmethyl cellulose  (HPMC  K4M),  Ethyl cellulose, 
Xanthan gum and Guar gum. In vitro drug release studies showed that the formulation 
containing HPMC K4M and ethylcellulose had sustained release up to 98% of 
Ranitidine hydrochloride over a period of 24h 
R. Gowri. et al., (2015)37formulated  floating tablets of Ranitidine  hydrochloride by 
wet granulation technique using the polymers such as different grades of  hydroxyl 
propyl methyl cellulose (HPMC K 100 M and HPMC K 15, HPMC E5)  and Carbopol. 
The physiochemical properties of different formulations, total buoyancy lag time and 
floating time were evaluated. The formulation containing equal concentration of HPMC 
K 15and HPMC K 100M per tablet have floating lag time of 90 sec and showed 98 % 
drug release at the end of 24 h with total floating time of more than 24h.Its drug release 
profile was fitted in various kinetic models and released that it follows zero order drug 
release following Higuchi model. 
Atul Mansing Kadam. et al., (2014)38formulated floating tablets of Ranitidine 
hydrochloride by direct compression method using HPMC K4M, HPMC K100M  as a 
synthetic polymers and Gellan Gum (low acyl) as a natural polymer and evaluated for  
pre compression and  post compression parameters. From the results it was revealed 
that formulation with drug: polymer ratio 5:4 exhibited sustained release of drug and 
followed Korsemeyer Peppa’s kinetics. Natural polymer (Gellan Gum) showed better 
results for sustained drug release properties than synthetic polymer. It was concluded 
that, Gellan gum shows more floating lag time than HPMC K4M and HPMC K100M 
respectively. The floating lag time was found to be significantly increased with increase 
in concentration of polymer. The  formulation F13, F14, F15 containing combination of 
polymers Gellan Gum and HPMC K4M shows that the drug release vary from 
88.87±2.12% to 94.29±1.73% respectively. 
M. Ehsanul H. Chowdhury. et al., (2013)39prepared floating tablets of Ranitidine 
hydrochloride by direct compression method, using polymers such as Hydroxy propyl 
methyl cellulose, Psyllium husk and Carbopol 934 in combination. Sodium bicarbonate 
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and citric acid was incorporated as a gas generating agent. All the batches showed 
floating time more than 12 hours. It is also observed that formulation containing highest 
combination of polymer shows better controlled release behaviour. 
K. Kavitha. et al., (2013)40formulated floating tablet of Ranitidine with low density 
polymers like hydroxyl propyl methyl cellulose and gas generating agents. Formulation 
was optimized on the basis of floating time and in vitro drug release. Four different 
formulations of Ranitidine were formulated by variation in the ratio of hydroxyl propyl 
methyl cellulose. It was found that Ranitidine incorporated with concentration of 33% 
of HPMC K15 found to be better formulation by considering all the evaluated 
parameters like floating lag time, total floating time, hardness, friability and weight 
variation and percentage drug release 98% drug release was observed in 24h 
S. Dhivyaet al., (2012)41Preparation of floating drug delivery system is to increase the 
safety of the drug and to extend its duration of action. This novel drug delivery system 
is essential for the drugs that are degraded in the intestine .This floating drug delivery 
system is aimed at providing increased bioavailability. Floating drug delivery system 
can be retained in the stomach for long time by formulating Ranitidine hydrochloride 
with low density polymers like hydroxyl propyl methyl cellulose and gas generating 
agents are added to the system to reduce the density of the system. Intimate contact of 
the drug with the absorbing membrane has the potential to maximize the drug 
absorption. The tablet was subjected to evaluation for physical characteristics like 
weight variation, hardness, friability, drug content uniformity, floating lag time and 
floating time and in vitro drug release. Three different formulations of ranitidine 
hydrochloride were formulated by variation in the ratio of hydroxy propyl methyl 
cellulose. From the investigation it’s found that Ranitidine hydrochloride incorporated 
with 120mg of HPMC was found to be better formulation by considering all the 
evaluated parameters like lag time, hardness, friability and weight variation and 
percentage drug release. 
 
Hindustan Abdul Ahad. et al., (2011)42formulated floating matrix tablets of 
Ranitidine hydrochloride by direct compression technique, using polymers such as 
hydroxyl propyl methyl cellulose, Carbopol 934 in combination. Sodium bicarbonate, 
citric acid and calcium carbonate were incorporated as a gas- generating agent. The 
calcium carbonate had dual action as it produces gas to float the tablets and act as an 
LITERATURE REVIEW 
 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore  Page 33 
 
antacid. Optimized floating matrix tablets containing hydroxyl propyl methyl cellulose 
K4M and Carbopol 934 showed no change in physical appearance, drug content or in 
dissolution pattern after storage at 40°C and relative humidity 75% for a period of 
3months 
Asnaashari et al., 201143developed metronidazole floating dosage forms that are 
designed to retain in the stomach for a long time. HPMC, psyllium and Carbopol in 
different concentrations were used as floating agents, and sodium bicarbonate was 
added as a gas-forming agent. Formulations containing HPMC as filler showed 
prolonged lag times for buoyancy. Adding psyllium to these formulations had reduced 
relative lag times. Overall, selected formulations were able to float immediately and 
showed buoyancy for at least 8 h. In general, these systems can float in the gastric 
condition and control the drug release from the tablets. 
Prajapati S et al., 201144 developed a floating matrix tablet containing Domperidone 
as a model drug. Polyethylene oxide (PEO) and hydroxypropyl methylcellulose 
(HPMC) were evaluated for matrix-forming properties. A simplex lattice design was 
applied to systemically optimize the drug release profile. The amounts of PEO WSR 
303, HPMC K15M and sodium bicarbonate were selected as independent variables and 
floating lag time, time required to release 50% of drug(t50) and 80% of drug (t80), 
diffusion coefficient (n) and release rate (k) as dependent variables. The amount of 
PEO and HPMC both had significant influence on the dependent variables. It was 
found that the content of PEO had dominating role as drug release controlling factor, 
but using suitable concentration of sodium bicarbonate, one can tailor the desired drug 
release from hydrophilic matrixes. The linear regression analysis and model fitting 
showed that all these formulations followed Korsmeyer and Peppa’s model, which had 
a higher value of correlation coefficient (r). The tablets of promising formulation were 
found to be stable for 3 months under accelerated (40°C / 75% RH) stability testing. 
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AIM & OBJECTIVES 
AIM: 
 To formulate and evaluate the floating drug delivery of Nizatidine and comparing the 
effectiveness of polymers by using semi synthetic and natural polymers on the release rate. 
OBJECTIVES: 
• To study the drug-excipients compatibility by using FTIR analysis. 
• To perform physicochemical characteristics of model drug nizatidine. 
• To fabricate effervescent floating tablets of Nizatidine by using polymers 
Tamarind seed Polysaccharide (Natural), and Hydroxy Propyl Methyl 
Cellulose (Semi-synthetic) as release retardant.  
• To perform Pre-formulation characteristics for the all formulations. 
• To perform the post formulation characteristics for the all formulation and 
compare invitro drug release study. 
• To select the optimized formulation based on the above studies. 
• To study the in vivo radiography study of prepared floating tablets. 
• To perform the accelerated stability studies of the optimized formulation 
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PLAN OF WORK: 
1. Literature survey  
2. Construction of standard calibration curve 
3. Collection and isolation of gums from of Natural sources 
4. Drug excipients compatibility studies using IR/ FTIR spectrophotometer 
5. Preparation of nizatidine formulation 
6. Pre-compression evaluations 
a. Bulk density 
b. Tapped density 
c. Angle of repose 
d. Hausner’s ratio 
7. Post formulation evaluation 
a. Weight variation test 
b. Thickness 
c. Hardness 
d. Friability 
e. Drug content 
8. In vitro buoyancy / floating study 
9. Total Lag floating time 
10. Swelling Index 
11. In - vitro dissolution studies 
12. Drug release kinetics model 
13. In vivo radiography study of optimized formulation 
14. Accelerated Stability studies 
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DRUGPROFILE45, 46, 47
 
 
DRUG CLASS: 
Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-
receptors, particularly those in the gastric parietal cells. 
It is inhibits stomach acid production, and commonly used in the treatment of 
peptic ulcer disease (PUD) and Gastro Esophageal Reflux Disease (GERD). 
It is considered a good candidate for incorporation in a gastro-retentive dosage 
form because this delivery system promotes local delivery of the histamine H2- receptor 
antagonist to the receptor of parietal cell wall. Local delivery increases the stomach wall 
receptor site bioavailability of the histamine H2-receptor antagonist to reduce acid 
secretion. The increase in acid-secretion reducing capacity is described as being 
advantageous in the treatment of ulcer patients. As its solubility decreases with increase 
in pH, it would be more beneficial to retain the drug in stomach (acidic environment) for 
prolonged duration to achieve maximum absorption and receptor site bioavailability. 
So, gastro retentive drug delivery system is desirable to prolong the residence 
time of the dosage form in the stomach until the drug is completely released from the 
system. 
 
Chemical name: N-(2-[(2-[(dimethyl amino) methyl] thiazol-4-yl) methylthio] ethyl) 
-N-methyl-2-nitroethene-1,1-diamine. 
 
 
 
Molecular formula: C12 H21 N5 O2 S2 
Molecular weight : 331.46 g/mol. 
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PHYSICAL PROPERTIES: 
Appearance  : Almost a white or slight brownish, crystalline powder 
Solubility   : Shows pH dependent solubility. 
Water solubility (mg/ml): > 100, 46.1, 26.7 (pH 5, 7, 9), 
 i.e., highly soluble in 0.1N HCl (pH 1.2). 
Partition co-efficient        :   0.7 
Melting range : 130-134oC 
   Storage   : Store at 20-25°C 
 
PHARMACOKINETICPARAMETERS 
Bioavailability : >70%  
Protein binding : 35% 
Half-life : 1-2hours 
Absorption : Stomach 
Metabolism : Hepatic  
Excretion : Renal 
Plasma clearance : 40 to 60 L/hr 
    Cmax                                      :      700 to 1,800 µg/L for a 150-mg dose and 
 1,400 to 3,600µg/L for a 300-mg dose. 
Tmax : 1.5hours 
Volume of distribution       :      0.8 to 1.5 L/kg. 
 
DOSAGE AND ADMINISTRATION: 
 Active duodenal ulcer:  
The recommended oral dose for adults is 300 mg once daily at bedtime. An 
alternative dosage regimen is 150 mg twice daily. 
 Maintenance of healed duodenal ulcer: 
The recommended oral dose for adults is 150 mg once daily at bedtime. 
 Gastro Esophageal Reflux Disease:  
The recommended oral dose in adults for the treatment of erosions, ulcerations, and 
associated heartburn is 150 mg twice daily. 
 Active benign gastric ulcer:  
The recommended oral dosage is 300 mg given either as 150 mg twice daily or 300 
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mg once daily at bedtime. Prior to treatment, care should be taken to exclude the 
possibility of malignant gastric ulceration. 
 
PEDIATRIC DOSING: 
 Erosive esophagitis: 
 For pediatric patients 12 years or older, the dose is 150 mg b.i.d. (300 mg/d). 
 Gastro Esophageal Reflux Disease:  
For pediatric patients 12 years or older, the dose is 150 mg b.i.d. (300 mg/day). The 
maximum daily dose for Nizatidine is 300 mg/day. The dosing duration may be up 
to eight weeks. 
 
SIDE EFFECTS: 
 Serious reactions: 
Hepatitis, Thrombocytopenic purpura, Exfoliative dermatitis, leukopenia, 
Pneumonia. 
 Common reactions: 
Headache, rhinitis, abdominal pain, nausea and dizziness. 
 
CONTRA INDICATIONS: 
Nizatidine is contraindicated in patients with known hypersensitivity to the drug. 
Because cross sensitivity in this class of compounds has been observed, H2-receptor 
antagonists, including Nizatidine, should not be administered to patients with a history of 
hypersensitivity to other H2-receptor antagonists. 
 
DRUG INTERACTIONS: 
       Nizatidine can potentially interact with a few other medicines. Some of the 
medicines that may lead to Nizatidine interactions include:  Aspirin, Atazanavir, 
Itraconazole, and Ketoconazole. 
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EXCIPIENT PROFILE 
TAMARIND SEED POLYSACCHARIDE48, 49, 50 
Tamarind, commonly known as Imli, is a rich source of tamarind gum or 
tamarind kernel powder 
Synonym:Tamarind Seeds Gum, Tamarind Kernel Powder. 
Origin:Tamarind is amongst most common and commercially important large evergreen 
tree that is grown abundantly in the dry tracks of central and south Indian states, and also 
in other south East Asian countries. Part of fruit of Tamarinds Indica Family -
Leguminosae 
     
 Fig .No15: Tamarind seeds 
Structure: 
 
 
Chemical Structure: 
Chemically,tamarind kernels powder is a highly branched carbohydrate 
polymer.Tamarind seeds polysaccharide is a polymer with an average molecular weight 
of 52350 Dalton’s and a monomer of mainly three sugars – glucose, galactose and 
xylose in a molar ratio of 3:2:1.  
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A polymer consists of cellulose type spine which carries xylose and 
galactoxylose substituents. About 80% of glucose residues are substituted by xylose 
residues (1-6 linked),which themselves are partially substituted by p-1-2 galactose 
residues. 
Chemical Composition: 
The composition of tamarind kernels powder, the source of gum resembles 
cereals with 12.7-15.4% of protein,3-7.5% of oil,7-8.4% of crude fiber,61-72.2% 
carbohydrates, and 2.45-3.3%of ash. All of this was measured on dry weightbasis. 
A polymer with an average molecular weight of 52350 Daltons and monomer 
of mainly three sugars – glucose,galactose and xylosein a molar ratio of 3:2:1. 
A polymer consists of cellulose type spine which carries xylose and 
galactoxylose substituents.About 80% of glucose residues are substituted by xylose 
residues (1- 6linked), which themselves are partially substituted by p-1-2 
galactoseresidues.Tamarind seed polysaccharides are a branched polysaccharide with a 
main chain of Β-D-1- glucopyrynosyl units with a main chain consisting of single D-
xylopyranosyl unit attached to every 2nd,3
rd
and 4
th
D glucopyrynosyl unit through1-
6linkage. 
General properties of Tamarind seed polysaccharide 
Purified Tamarind seed polysaccharide is a high-molecular- weight, neutral 
branched polysaccharides consisting of cellulose like backbone that carries xylose and 
galctoxylosesubstances. It is insoluble in organic solvents and dispersible in warm 
mater to form a highly viscous gel as a mucilaginous solution with a broad pH 
tolerance and adhesively.In addition, it is non-toxic and non-irritant with a hemostatic 
activity. It is a galactoxyloglucan, belongs to the xyloglucan family, and possesses 
properties such as non-Newtonian rheological behavior, mucomimetic, mucoadhesive 
and pseudo plastic properties. 
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Application: 
1. A novel polysaccharide named tamarind seed polysaccharide is now being used 
as an excipient in the hydrophilic drug delivery system because of its properties 
which include non–carcinogenicity, mucoadhesive and biocompatibility. High 
drug holding capacity and high thermal stability. There is a need to carry out 
further research on the efficacy of TSP as an excipient in 
pharmaceuticalformulation. 
2. Tamarind seed polysaccharide could be used as binder for wet granulation and 
direct compression tabletmethods 
3. Tamarind seed polysaccharide is useful for colon specific drug delivery because 
of biodegradable and hydrophilicnature. 
4. Tamarind Seed Polysaccharides is used for production of thickened ophthalmic 
solutions having a pseudo plastic rheological behavior and mucoadhesive 
properties. 
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HYDROXY PROPYL METHYL CELLULOSE (HPMC)51 
Non-Proprietary name  :BP-Hypermellose, 
USP-Hydroxy propyl methylcellulose 
Synonym :Methyl hydroxy propyl cellulose, Methylcellulose, 
Chemicalname :Cellulose 2- hydroxy propyl methylether 
Molecularformula :[C6H7O2(OH)3—(OCH3)—(OCH3CH(OH)—CH3)]n 
Molecularweight :Approximately 86,000Dalton’s 
Chemical structure 
 
Category :Tablet binder, film former, coating agent, suspending 
agent, and stabilityagent. 
Description  :White (or) yellowish white fibrous (or) granular 
powder, almost odorless, hygroscopic afterdrying 
Solubility   :Solublein mixtures of ethanol and methylene chloride, 
practically insoluble in hot water, acetone, ethanol, 
toluene, and ether. It swellsby cold water forming an 
opalescent viscous colloidalsolution 
Meltingpoint  :190-200ºC 
Acidity/alkalinity :5.5- 8.0 for 1% w/w aqueoussolution 
Specificgravity  :1.26w/v 
Density   :0.25- 0.71g/cm3 
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Viscosity   :HPMCK100M 80,000-12,0000 cps  
   HPMCK4M 3000-5000 cps  
   HPMCE5 5cps 
   HPMCE15 15cps 
Stability : Bulk materials stored in an air tight container and in 
cold and dryplace. 
 Increase in temperature decrease the viscosity of the 
solution. 
Safety : It was regulated as non-toxic (or) non-irritant although 
excessive consumption causes laxativeeffect 
 
Application: 
1. Used in the treatment of tear deficiency. 
2. It was versatile and granular agent. 
3. It swells by water and in virtually in all GIT fluids and it may except to retard 
disintegration and dissolution time of drug in the tablets when wet granulation is 
employed 
Table No.4 : Application of HPMC based on concentration 
 
Uses Concentration (%) 
Extended release matrix 
formulation 
15-35 
Tablet binder 2-6 
Tablet film coating 2-20 
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CITRIC ACID52 
 
Synonym :2hydroxy propane1,2,3,tricarboxylic acidmonohydrate 
Non-Proprietary Names :BP-Citric acidmonohydrate; 
USP : Citricacid 
ChemicalName : 2-hydroxy-1,2,3-propanetricarboxlic acidmonohydrate 
Chemicalformula : C6H8O7.H2O 
Molecularweight : 210.14 
Chemical structure 
 
Category :Acidifying, antioxidant, buffering agent, chelating, 
flavorenhancer 
Description :It is colorless (or) transculant (or) as a whitecrystalline 
efflorescent Powder. It is odorless and has strong acid 
flavor, the crystal structure is orthorhombic 
Solubility :Soluble in 1.5 parts of ethanol (95%) and 1 in less 
than1 partof water, sparingly soluble inether. 
Typical properties 
Acidity/alkalinity : pH 2.2 for a (1% w/v aqueoussolution) 
Density :1.54g/cm3 
Meltingpoint :100ºC 
Viscosity (dynamic)  :65 cps for aqueous solution at 25ºC 
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Storage :The bulk monohydrate (or) anhydrous material should 
be stored in airtight container in a cool, dryplace 
Safety : Orally ingested citric acid is absorbed and is generally 
regarded as a nontoxicmaterial. 
Applications: 
 
1. Citric acid monohydrate is used in the preparation of effervescent granules, while 
anhydrous citric acid is widely used in the preparation of effervescenttablets. 
2. Citric acid has also been shown to improve the stability of spray-dried insulin powder 
in inhalationformulations. 
3. In food products, citric acid is used as a flavor enhancer for its tart, acidictaste. 
4. Citric acid monohydrate is used as a sequestering agent and antioxidantsynergist. 
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SODIUM BICARBONATE53 
 
Synonym :Sodium hydrogen carbonate, Monosodium 
carbonate,Sodium acidcarbonate 
Non-Proprietary name :BP-Sodiumbicarbonate 
Chemicalname :Carbonic acid monosodiumsalt 
Chemicalformula :NaHCO3 
Molecularweight :84.01 
Chemical structure 
 
Category :Alkalizing agent, therapeuticagent 
Description :Odorless, white crystalline powder, slightly alkaline 
Solubility : Soluble in water, 
  practically insoluble in ethanol and ether  
Typicalproperties: 
 
Acidity/alkalinity :pH 8.3 for a freshly prepared 0.1 M aqueous solution at 
25°C alkalinity increase on standing, 
agitation,(or)heating 
Density :0.869-2.173g/cm3 
Freezingpointdepression :0.381°C  
Meltingpoint :270°C 
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Applications: 
 
1. Sodium bicarbonate   is   generally   used   in   pharmaceutical   formulations   as a 
source of carbon dioxide in effervescent tablets andgranules. 
2. It is also widely used to produce or maintain an alkaline pH in apreparation. 
 
3. In effervescent tablets and granules, sodium bicarbonate is usually formulated with 
citric and/or tartaricacid. 
4. Sodium bicarbonate may be used as an antacid, and as a source of the bicarbonate 
anion in the treatment of metabolicacidosis. 
5. Sodium bicarbonate may also be used as a component of oral rehydration salts and as a 
source of bicarbonate in dialysisfluids. 
 
Table 5:  Application of Sodium bi carbonate 
 
Uses Concentration (%) 
Buffer in tablet 10-40 
 
Effervescent tablet 
 
25-50 
Isotonic injection/ 
infusion 
1.34 
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MICROCRYSTALINECELLULOSE54 
NonproprietaryNames : BP: Microcrystalline  
   USP-NF:     Microcrystalline Cellulose 
Synonyms : Avicel, cellulose gel, crystalline cellulose, E460, 
Emocel, Fibrocel, Tabulose,Vivacel. 
Functional Category : Tablet and Capsule diluent, suspending agent, 
adsorbent, tabletdisintegrant. 
Description : White-colored, odorless, tasteless crystalline powder 
composed of porous particles. Available in different 
particle size grades which have different properties 
andapplications. 
Solubility : Slightly soluble in 5 % w/v NaOH solution, practically 
insoluble in water, dilute acids and most 
organicsolvents. 
Stability  : It is a stable, though hygroscopicmaterial. 
Storage conditions : The bulk material should be stored in a well-closed 
container in a cool and dryplace. 
Incompatibilities  : Incompatible with strong oxidizingagents. 
Safety  : It is generally regarded as a nontoxic and 
nonirritantmaterial. 
Applications: 
 
1. Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compressionProcesses. 
2. In addition to its use as a binder/diluent, microcrystalline cellulose also has some 
lubricant and disintegrates properties that make it useful intableting. 
3. Microcrystalline cellulose is also used in cosmetics and foodproducts 
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MAGNESIUM STEARATE55 
Non-proprietarynames :BP- Magnesium Stearate  
  JP- Magnesium stearate 
Synonyms : Magnesium octadecenoate, octadecanoic acid 
magnesium salt and stearic acid magnesiumsalt. 
Chemical name  : Octadecanoic acid magnesium salt 
Structural formula  : [CH3 (CH2)16COO] 2Mg 
Molecular weight  :591.34 
Chemical structure 
  
Functional category  : Tablet and capsulelubricant. 
Melting point   : 117-1500C 
Description : Magnesium stearate is a fine, white, precipitated or 
milled, impalpable powder of low bulk density, having 
a faint odor of stearic acid and a characteristic taste. 
The powder is greasy to touch and readily adheres to 
theskin. 
Solubility : It is practically insoluble in ethanol (95%), ether and 
water; slightly soluble in warm benzene and warm 
ethanol (95%). 
Applications : It is widely used in cosmetics, foods and 
pharmaceutical formulations. It is primarily used as a 
lubricant in the manufacturing of tablets and capsules, 
in the concentration of 0.25-5.0%. It is also used in 
barriercreams. 
Stability & storage conditions:It should be stored in a well closed container in a cool, 
dryplace. 
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TALC56 
Non-proprietarynames  :BP- Purified talc  
  USP- Talc 
Synonyms : Altalc, powdered talc, purified French chalk, Pure   
talc,soapstone, steatite andSuperior. 
Chemical name  :Talc 
Structural formula  : Mg6(Si2O5)4(OH)4 
Molecular weight  :379.2 
Chemical structure  
 
Functional Category :Anticaking agent, glidant, tablet and capsulelubricant 
Description :Talc is very fine; white to grayish 
white,odorless,crystalline powder, it adheres readily to 
the skin and is so soft to touch and free fromgrittiness 
Solubility :It is practically insoluble in dilute acids and 
alkalis,organic solvents and water. 
Typical properties 
 
Acidity/alkalinity :pH 7-10 for a 20 % w/v aqueousdispersion 
 
Stability :Talc is a stable material and may be stored by heating at 
160ºC for not less than 1hour 
Incompatibilities  : It is incompatible with quaternary ammonium 
compounds 
Storage :Talc should be stored in a well closed container in a 
cool, dry place 
Stability & storage conditions : It is a stable material and may be sterilized by heating 
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at 160°C for not less than 1 hour. It may also be 
sterilized by exposure to ethylene oxide or gamma 
irradiation. It should be stored in a well closed 
container in a cool and dryplace. 
Applications: 
 
1. It is used as a diluent, lubricant in tabletformulations. 
 
2. In a novel powder coating for extended-release pellets and as anadsorbent. 
 
3. In topical preparations, it is used as a dusting powder, usedtoclarify liquids. 
 
4. It is also used in cosmetics and foodproducts. 
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FORMULATION DEVELOPMENT: 
1. Isolation of Tamarind seed polysaccharide49 : 
The seeds of Tamarinds indica are washed in water to 
remove the adhering materials 
    
By heating seeds in sand ratio of 1:4 c 
 
 
Reddish Testa of the seeds is removed  
   
Seeds are crushed lightly 
   
 
 Crushed seeds are soaked in water for 24 h 
 Boil for 1 hour 
Kept aside for 24hr for the release of mucilage into 
water 
 
 
Soaked seeds are squeezed in a muslin bag to remove 
marc 
 
From the filtrate 
  
 
Equal quantity of acetone is added to precipitate the 
mucilage 
 
 
 
Separate the mucilage&  
Dried at temperature500c  
  
 
 
Powdered and passed through sieve number 80. 
   
 
 
Stored in airtight container at  room 
temperature. 
 
Fig.No.16:Isolation of Tamarind seed polysaccharide 
 
 
Tamarind seed: sand
 
Removed Testa 
 
Crushed Seeds 
 
Mucilage
 
Powder polymer 
 
Stored polymer 
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FORMULATION OF NIZATIDINE FLOATING TABLET: 
Direct compression: 
   The Nizatidine floating tablets was prepared by effervescent technique used 
the hydrophilic polymers (HPMC K4M, and Tamarind seed polysaccharides). Sodium bi 
carbonate & citric acid used as gas generating agent. The polymers were chosen as they are 
well established in the similar studies and have great swelling and controlled release 
properties respectively. In direct compression vehicles can be used which are having good 
free flow properties, no segregating and are have compressible mixture. 
Steps involved in preparation of floating tablet by direct compression: 
Drug (Nizatidine) + Different polymers in various ratios + NaHCO3+ Citric acid + 
Talc +Magnesium stearate 
 
Were mixed in mortar with the help of pestle 
& add MCC and triturate well 
 
 Blended materials compressed on 12.5mm flat round punches 
& corresponding dies are used 
 
The Total weight of the prepared tablet was maintained as 500mg 
 
Nizatidine with the other excipients are in concentration & ratio are used for the 
preparation of tablet were shown in Table. 6 
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Table.6: Formulation of Nizatidine floating tablets 
 
 
INGREDIENTS  
FORMULATION CODE 
F1 mg  F2 
mg  
F3  
mg  
F4 mg  F5 mg  F6 
mg 
F7 
mg 
F8 
mg  
F9 mg 
Nizatidine 150 150 150 150 150 150 150 150 150 
Tamarind 
polysaccharide 
(1:0.5, 1:1, 1:1.5) 
 
75 
 
150 
 
225 
 
- 
 
- 
 
- 
 
37.5 
 
75 
 
112.5 
HPMC K4 
(1:0.5, 1:1, 1:1.5) 
- - - 75 150 225 37.5 75 112.5 
Sodium 
bicarbonate (10%) 
35  35  35  35  35  35  35  35  35  
Citric acid (1%) 4 4  4  4  4  4  4  4  4  
Talc (1.7%) 6 6  6  6  6  6  6  6  6  
Magnesium 
stearate (4%) 
   4 4  4  4  4  4  4  4  4  
Microcrystalline 
cellulose (14%) 
50  50  50  50  50  50  50  50  50  
Lactose (q. s) 176 101 26 176 101 26 176 101 26 
Total weight  500 500  500  500  500  500  500  500  500  
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     MATERIALS AND EQUIPMENTUSED 
Table. 1: Materials used in the study 
 
S.No. Name of chemical Manufacturer/supplier 
1 Nizatidine Central Drug Laboratory, Chennai 
2 HPMC K4M Hi Media Laboratories limited, Mumbai 
3 Carbopol Hi Media Laboratories limited, Mumbai 
4 MCC SD Fine chem. Ltd, Mumbai 
5 Sodium bi carbonate SD Fine chem. Ltd, Mumbai 
6 Citric acid SD Fine chem. Ltd, Mumbai 
7 Magnesium stearate SD Fine chem. Ltd, Mumbai 
8 Talc SD Fine chem. Ltd, Mumbai 
9 Conc. Hydrochloric acid SD Fine chem. Ltd, Mumbai 
 
10 Acetone Hi Media Laboratories limited, Mumbai 
11 Tamarind Seed Local market, Trichy 
 
Table. 2: Equipment used in the study 
 
S.No. Equipment Model no. Manufacturer 
1 Tablet Punching Machine Mini press-I Rimek, Ahmedabad 
2 Digital Weighing Balance AX 200 Shimadzu 
Corporation,,Japan 
3 pH Meter Cyber Scan EutechInstrument,Sing
apore 
4 Bulk and tapped density 
apparatus  1951 Digital 
Thermonik,Campbell 
electronics, Mumbai, India  
5 Hardness Tester Monsanto hardness tester Praveen Enterprises, 
Bangalore. 
6 Vernier caliper Aerospace 150 mm 
Digimatic 
Linker, Mumbai. 
7 Friability (USP) C-FTA20 Thermonik, Campbell 
electronics 
8 Dissolution Apparatus 6 stage dissolution rate 
test apparatus IP/BP/USP 
TAB Machines, 
Mumbai 
9 UV–Visible 
Spectrophotometer 
UV-1700 Pharmaspec, Shimadzu 
10 FTIR Spectrophotometer FTIR-8400S Japan 
11 Glass ware 
Borosilicate 
Mumbai, India 
12 Heating mantle 
- Sunbim , India  
 
 EXPERIMENTAL PROTOCOL 
 
 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore Page 56 
 
 
EXPERIMENTAL PROTOCOL 
1. Solubility study of Nizatidine in 0.1 N HCl 
 
Nizatidine was placed in 0.1 N HCl in order to determine its solubility. The sample was 
shaken for 24 hrs at 37 °C in a horizontal shaker. The supernatant was filtered and the filtrate 
was diluted with the 0.1 HCl and assayed by UV-Visible spectrophotometer at λmax314 nm. 
 
Table No.7: Solubility profile I.P. 1996 
 
Descriptive Term Parts of Solvent required for 1 part of Solute 
Very soluble >1 
Freely soluble 1-10 
Soluble 10-30 
Sparingly soluble 30-100 
Slightly soluble 100-1,000 
Very slightly soluble 1,000-10,000 
Practically insoluble >10,000 
 
 
Preparation of Simulated gastric fluid without enzyme (SGF) 
 
About 2.0g of sodium chloride and 7.0ml of hydrochloric acid (concentrated) were 
dissolved in small amount of distilled water and made upto to 1000ml with distilled water 
whose pH 1.2 
a. Calibration Curve of Nizatidine in 0.1 N HCl in SGF 
 
Taken into different volumetric flasks and volume were made up to 100 ml with Acid 
buffer pH 1.2 solution, so as to get concentration of (20-100 μg/ml). The absorbance of these 
solutions were measured at 314 nm by UV Spectrophotometer. A calibration curve is plotted 
by taking concentration on X-axis and absorbance on Y-axis to obtain the standard curve.  
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2. DRUG EXCIPIENTS COMPATIBILITY STUDIES 
 
a. Physical Incompatibility: 
 
 
  Table. No. 8: Ratio for Physical Incompatibility studies 
 
 
S.NO 
 
INGREDIENTS 
 
DRUG 
EXIPIENTRATIO 
1 Nizatidine - 
2 Drug + Tamarind Polymer 1:1 
3 Drug+HPMC 1:1 
 
4 Drug+NaHCO3 1:1 
5 Drug+Citricacid 1:1 
6 Drug+Talc 1:1 
7 Drug+MCC 1:1 
8 Drug+MagnesiumSterate 1:1 
 
Chemical Incompatibility: 
 
b. Fourier Transform Infrared (FTIR)Spectroscopy: 
    
Infrared spectroscopic analysis was performed to check out the compatibility between 
the drug (Nizatidine) and the hydrophilic polymers (HPMC K4M) and Tamarind seed 
polysaccharides used in the formulation of floating matrix tablets. IR spectrum of the pure 
drug and the physical mixtures of drug with polymers of optimized formulation were 
studied.  
.  
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3. PRE FORMULATION 
a. Angle of repose: 
 Angle of repose is define as the maximum angle possible between the surface of 
the pile of powder and the horizontal plane. The angle of repose is designated θ is given by 
equation:   
     θ= tan-1 (h/r) 
   Where, h is height of pile in cm, 
        r= radius of pile in cm, 
    θ = angle of repose. 
The fixed funnel method is to measure the angle of repose. The funnel height is maintained 
approximately 2 - 4 cm from the top of the powder pile in order to minimize the impact of 
falling powder on the tip of the cone. The blend carefully pored through the funnel. The 
height ‘h’ of the pile from base and radius ‘r’ of the base of the conical pile is measured. 
    TableNo.9: Range for Angle of repose 
Angle of repose 
(θ) (degrees) 
Flow Type 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
c. Bulk density (Db): 
 It is the ratio of mass of powder to bulk volume. The bulk density depends on 
particle size distribution, shape and cohesiveness of particle. Accurately weighed quantity of 
powder was carefully poured into graduated measuring cylinder through large funnel and 
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volume was measured ‘as it as’ which is called initial bulk volume. It is expressed in gm/ml 
and is given by, 
 
    Db = M / V0 
   Where, 
 M is mass of a Powder 
    V0 is the bulk volume of the powder  
d. Tapped density:  
Ten gram of powder was introduced into a clean, dry 100ml measuring cylinder. The 
cylinder was then tapped 250 times from a constant height and the tapped volume was read. 
It is expressed in gm/ml and given by, 
    Dt = M / Vt 
   Where,  
M is mass of powder 
    Vt is the bulk volume of the powder  
e. Compressibility index (or) Carr’s Index (I) 
Compressibility index is an important measure that can be obtained from the bulk and 
tapped densities. It indicates the ease with which a material can be induced to flow powder 
flow properties. It is expressed in percentage and given by,      
I = Dt – Db / Dt × 100 
 
Where,  
I is the Compressibility index,  
Dt is the tapped density of the powder and  
Db. is the bulk density of the powder. 
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Table. No. 10 Range for Compressibility index (%) 
Compressibility index (%) Type of flow 
5-15 Excellent 
12-18 Good 
18-23 Fair 
23-35 Passable 
35-38 Poor 
>38 Very poor 
 
 e. Hausner’s ratio: 
It indicates the flow properties of the powder. The ratio of Tapped density to 
bulk density of the powder or granules is called Hausner’s ratio. 
H = Dt / Db 
Where, 
 H is the Hausner’s ratio,  
Dt is the tapped density of the powder and  
Db is the bulk density of the powder. 
Table. No. 11 Range for Hausner’s ratio 
 
 
 
 
 
 
 
 
 
 
 
Hausner’s ratio Type of flow 
1- 1.11 Excellent 
1.12- 1.18 Good 
1.19- 1.25 Fair 
1.26- 1.34 Passable 
1.35- 1.45 Poor 
1.46- 1.54 very poor 
>1.60 very very poor 
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4. POST - COMPRESSION PARAMETERS 
a. General appearance: 
The formulated tablets are evaluated for general appearance. Viz., color, odour, shape. 
b. Thickness and Diameter: 
They are measured by using Vernier calliper.  Five tablets were selected randomly 
from each batch and thickness and diameter were measured .It was expressed in (mm). 
c. Hardness Test: 
The Monsanto tester was used to determine the tablet hardness. The tablet was held 
between a fixed and moving jaw. Scale was adjust to zero; load was gradually increased until 
the tablet fractured. The value of the load at that point gives a measure of hardness of the 
tablet. Hardness of about 6.26 to 7.2 was considered to be minimum for uncoated tablets for 
mechanical stability. It was expressed in kg/cm2 
d. Friability Test: 
Tablet strength was tested by Roche friabilator. Pre weighed tablets were allowed for 
100 resolutions in 4 min and were dedusted. The percentage weight loss was calculated by 
reweighing the tablets. Compressed tablets should not loss more than 1% of their initial 
weight. The % friability was then calculated by; 
    F= (W initial) – (W final) X 100      
      (W initial) 
 e. Weight Variation as Per IP: 
Randomly selected twenty tablets were weighed individually and together in a single 
electronic pan balance. The average weight was noted and calculated standard deviation. The 
percentage weight variation as per Official limits are as shown in the Table. No.   It can be 
calculated by, 
PD = (W avg ) – (W initial) / (W avg) x 100 
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Where,  
PD= percentage deviation,  
W avg =Average weight of tablet, 
W initial = Individual weight of tablet 
Table No. 12: Official limits for weight variation 
Average weight of 
Tablet 
(mg) 
Percentage 
Deviation 
(%) 
80 or less 10 
80 to 250 7.5 
More than 250 5 
 
f. Drug content uniformity: 
Ten tablets are weighed and taken in a mortar and crushed to make powder form. A 
quantity of powder weighing equivalent to 10mg of drug is taken in a 100ml volumetric flask 
and Acid buffer PH 1.2 is added. The solution is filtered using membrane filter (0.45μm) and 
10 ml of filtrate is taken into 100 ml volumetric flask and made up to final volume with Acid 
buffer PH 1.2. Then its absorbance is measured at 314 nm using UV Visible spectrometer. 
The amount of drug present in one tablet is calculated using standard graph. 
g. Swelling index:  
The swelling of the polymers can be measured by their ability to absorb water and 
swell.  The water uptake study of the tablet was done using beaker containing respective 
medium and it was maintained at 37 ±0.5◦ C throughout the study. After a selected time 
interval at 8hrs, the tablets were withdrawn, blotted to remove excess water and weighed. 
Swelling characteristics of tablets were expressed in terms of water uptake. The percentage 
of swelling index was calculated by, 
   S.I (%) =Weight of the swollen tablet - Initial weight of the tablet 
        Initial weight of the tablet 
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5. IN VITRO BUOYANCY DETERMINATION:  
a. Floating properties of the tablet (Floating lag time and total floating time):  
The time taken for tablet to float on surface of medium is called  the floating lag  time 
(FLT) and duration of the dosage form to constantly remain on surface of medium is called 
the total floating time (TFT). The in vitro buoyancy was determined by floating lag time total 
floating time. The tablets were placed in a 100 ml beaker containing SGF pH 1.2. The time 
required for the tablet to rise to the surface and float was determined as floating lag time and 
total floating time. 
6. IN VITRO DRUG RELEASE STUDIES:  
 
Dissolution characteristics of the formulated floating tablets of Nizatidine are carried 
out using USP Type II (paddle) dissolution test apparatus for 12hrs. 
Method: 
 
900 ml of acid buffer pH 1.2 was filled in dissolution vessel and temperature of the 
medium is set at 37°C ± 0.5°C. One tablet of different batch is placed in each dissolution 
vessel and the rotational speed of paddle was set at 75rpm. 5ml of sample is withdrawn at 
pre-determined time interval of every one hour for up to 12 hours and same volume of fresh 
medium is replaced immediately. The withdrawn sample is diluted to 10ml in volumetric 
flask and filtered through 0.45μ membrane filter. The resultant samples are analyzed for 
drug content at 314 nm using UV-Visible spectrophotometer. Parameters for in vitro studies 
are shown in Table. No.13 
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Table. No. 13 Parameters Performed in vitro studies 
Parameter Specifications 
Dissolution Medium Buffer 0.1N hydrochloric Acid 
Temperature 37.0 ± 0.5 °C 
Initial Volume 900ml 
Rotation Speed 75rpm 
Drawn Volume 5ml 
Running Time 12 hrs. in 0.1N hydrochloric Acid 
 
7. IN-VITRO DRUG RELEASE KINETICS 66 
 
To analyze the In-vitro release data various kinetic models were used to describe the 
release kinetics. The zero-order rate describes the systems where the drug release rate is 
independent of its concentration. The first order describes the release from the system where 
release rate is concentration dependent. Higuchi described the release of drugs from 
insoluble matrix as a square root of time dependent process based on the Fickian diffusion. 
The Koresmeyer- Peppa’s describes the mode of release of drug from swellable. 
Table. No.14: Equations of Release Kinetics Model 
 
Release Kinetics Model Equation 
Zero Order Qt = Q0 + K0.t 
First Order In Qt = In Q0 + K0.t 
Higuchi model Q = KH. t1/2 
Korsmeyer – Peppa’s Mt / M0 = a.tn 
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Where, 
Qt is amount of drug release at time t, 
Mt is drug release at time t, 
M0 is total amount of drug in dosage form, 
F is fraction of drug release at time t, 
K0is zero order release rate constant, 
Q0is Initial amount of drug in the solution (Most times, Q0=0)  
KH is Higuchi’s square root of time release rate constant, 
Km is constant depend on geometry of dosage form and 
n is diffusion exponent values indicating the mechanism of drug release. 
 
Fitness of release profiles to linear equations is assessed by comparing the 
coefficients of determination (regression) values. 
          Table. No. 15.Diffusion exponent values indicating drug release mechanism 
 
 
S. No. Diffusion exponent value (n) Drug release mechanism 
1 < 0.5 Fickian release 
2 0.5 to 1.00 Non-Fickian transport 
3 1.00 Case II transport 
4 > 1.00 Super case II transport 
 
The in-vitro release data are fitted to the above mathematical models and the 
applying data are, 
 Cumulative % drug release vs. time for zero order kinetic. 
 Log cumulative of % drug remaining vs. time for first order kinetic. 
 Cumulative % drug release vs. Square root of time for Higuchi model. 
 Log cumulative % drug release vs. log time for Korsmeyer- Peppa’s model. 
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8. SELECTION OF BEST FORMULATION: 
  Selection of best formulation were depends on best fit parameters of FLT, TFT, 
Swelling index, in vitro drug release, in vitro kinetic release 
9. IN VIVO X-RAY STUDIES: 
a. Animal and diet: 
• The male albino rabbit (2 - 2.5kg) are housed in the polypropylene cages at temperature 
22 ± 2 ͦc. The animal is fasted overnight but allowed to take water ad libitum (Londhe S 
et al., 2010).  
• Then 30 ml of 5 % dextrose solution is given immediately before administering the 
tablet by using stomach tube (No. 12 French Catheter) and 20 ml syringes. 
• The experiment protocol of the study was approved by Institutional Animal Ethical 
Committee (Registration No. KMCRET/M. Pharm/01/2018-2019) 
 
b. In vivo X-ray of optimized formulation: 
 
• The in-vivo X-ray studies were performed in healthy male albino rabbit. 
• After performing physicochemical characteristics. In- vitro buoyancy, In vitro drug 
release and swelling index, among all formulations, F8 formulation containing 
combination of tamarind seed polysaccharides & HPMC K4M polymer(1:1)have shown 
best and satisfactory results.  
• Hence, this formulation was selected for further In vivo evaluations. The optimized 
formulation was prepared using 25% of drug was replaced with barium sulphate are made 
opaque, with no changes in other ingredients. 
• The in-vivo radiographic studies were performed in healthy male albino rabbit in the 
abdominal region, and photographs are taken at 0, 2, 4, 6, 8, 10 & 12 hrs by using x-ray 
machine. 
• The in-vivo radiographic studies were performed in healthy male albino rabbit at 
appropriate periodic time intervals by using x-ray machine. 
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• .After administration of tablet. At hourly intervals 30 ml of 5% dextrose solution 
is given to maintain optimum fluid level in the stomach. The gastric residence 
time is observed. 
 
10. EVALUATION OF ACCELERATED STABILITY STUDIES BEST 
FORMULATION (F8): 
  Stability studies were carried out by using selected formulation i.e. F8. The 
formulation is kept in accelerated stability condition at temperature 40˚C/75% relative 
humidity for a period of 2 months as per International Conference on Harmonization 
guidelines. 
  The samples were withdrawn after 60 days intervals and evaluation was carried 
out for appearance, thickness, hardness, buoyancy lag time, drug content and In-vitro release 
studies (60days) were performed. 
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1. SOLUBILITY OF NIZATIDINE
Nizatidine is highly soluble in 0.1 N HCl, having quantitative solubility99.20 mg/ml.
a.CALIBRATION CURVE OF NIZATIDINE in 0.1 N HCl (pH 1.2)
Scanning of the volumetric solution to nizatidine in ultraviolet range (200-400nm) 
against   0.1N HCl blank gave the λmax at 314nm. The standard concentrations of 
Nizatidine (20-100 μg/ml) prepare as 314 nm and there absorbance are shown in Table. 
No.16 The standard concentrations of Nizatidine (20-100 μg/ml) showed good linearity 
with R2 value of 0.9998, were shown in Fig.No.which suggests that it obey the Beer-
Lamberts law.
Table.No.16: Absorbance of Nizatidine in 0.1 N HCL (pH 1.2)
Concentration 
(µg/ml)
Absorbance
0 0
20 0.073
40 0.138
60 0.203
80 0.268
100 0.339
Fig. No. 31Calibration curve of Nizatidine in 0.1 N HCl at 314 nm
y = 0.0034x + 0.0027
R² = 0.9998
0
0.1
0.2
0.3
0.4
0.5
0 50 100 150
Absorbance (nm)
Calibration curve of Nizatidine in 0.1 N HCl at 314 
nm
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2.DRUG EXCIPIENTS COMPATIBILITY STUDIES
a.Physical Incompatibility:
There is no interaction between drug and excipientsbased on the physical 
appearance and the result werementioned in Table. No:17
Table.No.17: Physical Incompatibility
S.NO INGREDIENTS DRUG 
EXIPIENTRATIO
OBSERVATION
1 Nizatidine - Off white 
crystalline powder
2 Drug + Tamarind 
Polymer
1:1 Off white 
crystalline powder
3 Drug+HPMC 1:1 Off white 
crystalline powder
4 Drug+NaHCO3 1:1 Off white 
crystalline powder
5 Drug+Citricacid 1:1 Off white 
crystalline powder
6 Drug+Talc 1:1 Off white 
crystalline powder
7 Drug+MCC 1:1 Off white 
crystalline powder
8 Drug + 
Magnesium 
Sterate
1:1 Off white 
crystalline powder
b. Chemical Incompatability:
Fourier Transform Infrared (FTIR) Spectroscopy:
From the Fig. No. the majors peaks were obtained at 765, 1226 , 1393 and 3000-
2968/ cm-1 for pure drug of some functional groups of N-H, C-N, C=C, CH3 of 
respectively. Ranges were shown in Table.No.18
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Fig.no.32 FT-IR Spectra of Nizatidine pure drug
Fig.no. 33.FT-IR Spectra of Nizatidine + Tamarind polysaccharide
Fig.no.34. FT-IR Spectra of Nizatidine + HPMC K4
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Table No.18: FTIR SPECTRA OF DRUG AND EXCIPIENTS
The major peaks obtained a pure drug in the same characteristic bands drug in 
excipients also shown, without any significant spectral changes thus there is no interaction 
between the drug and excipients used in the formulations.
3. PRE-FORMULATION
a. Angle of repose:
The Angle of repose for all formulations was in the range of 25042’ to 
28072’whichindicates good flow of the powder,were shown in Table. No.19
b. Bulk density (Db):
The Bulk density of the powder was in the range of 0.66 to 0.74 gm/cc, which 
indicatesthe powder
were shown in Table.No.19
c. Tapped density (Dt): 
The Tapped density of the powder was in the range of 0.74 to 0.83 gm/cc, were
shown in Table.No.19
d. Compressibility index (or) Carr’s Index(I):
The Compressibility index(or) Carr’s Index was found to be in range 9.2 to 11.96% , 
which support fact that these formulation has excellent  flow and compaction 
propertieswere shown in Table .No.19
Specified functional 
group
Nizatidine Nizatidine + 
Tamarind
Nizatidine 
+HPMC
CH3 2968 2956 2968
NH 3300 3306 3300
N-O 1393 1390 1395
C-S 765 751 769
C-N 1301 1334 1330
C=C 1393 1390 1380
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e. Hausner’s ratio:
The Hausner’s ratio was found to be in the range of 1.102 to 1.135 which was
supports the fact that the formulation has good and excellent flow abilitywere shown in 
Table No.19
All formulation were exhibit good flow property and compressibility which is very 
essential for direct compression and hence tablets were prepared by using direct 
compression technology.
Table No.19: Pre-Formulation (Pre-Compression)
4. POST-COMPRESSION PARAMETERS
a. Generalappearance:
The formulated tablets were evaluated for general appearance. Viz., color, odour, 
shape were good as shown in Table. No.20
b. Thickness and Diameter:
The Thickness of tablet were measured using venier caliper. The Thickness was 
found to be 4.12 to 4.29 mm and diameter were in 11mm as shown in Table. No.20
c. Hardness Test:
The measured hardnessof all batches of tablet was found to be in the range of 6.26 to 
7.2 kg/ cm2as shown in Table. No.20These ensure good handling characteristics of tablets.
Formulations
Angle of  
repose
± SD
Bulk density
(gm/ml)
Avg ±S.D
Tapped
density(gm/ml)
Avg ±S.D
Carr’s 
index 
(%)
Hausner’s 
ratio
F1 25042’ ± 1.11 0.742± 0.002 0.818± 0.002 9.24 1.102
F2 25069’ ± 1.51 0.660± 0.002 0.740± 0.002 10.810 1.121
F3 27047’ ± 1.63 0.731± 0.003 0.821± 0.003 10.962 1.123
F4 26094’ ± 0.56 0.714± 0.004 0.789± 0.003 10.504 1.105
F5 26005’ ± 1.48 0.740± 0.003 0.823± 0.002 10.085 1.112
F6 28068’ ± 1.82 0.721± 0.002 0.818± 0.002 11.858 1.134
F7 26029’ ± 0.51 0.734± 0.002 0.810± 0.002 9.382 1.103
F8 25060’ ± 0.92 0.728± 0.004 0.826± 0.002 11.86 1.134
F9 28072’ ± 1.48 0.736± 0.004 0.836± 0.002 11.96 1.135
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d. Friability Test:
The maximum friability of the formulation was found to be 0.89%. The minimum 
friability of the formulation was found to be 0.82% were shown in Table.No.20 The 
friability was less than 1% in all the formulations ensuring that the tablets were found 
mechanically stable.
e. Weight Variation as Per IP:
All the formulated tablets passed the percentage weight variation as per IP limits of 
±5% to the weight as shown in Table. No.20 The weights of the all the formulated tablets 
were found to be uniform. The prepared formulation complies with the weight variation 
test.
f. Drug content uniformity:
The drug estimation data for all the formulated tablets were found to be within the limit 
and the result as shown in Table. No.20
g. Swelling index:
Swelling index for all formulations was carried out in the 0.1N HCl. F8 were shown 
maximum Swelling in 8hr with highest swelling index when compare to other all 
formulations as shown in Table. No.20
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Table No.20: POST FORMULATION STUDIES
Formulations Average 
Weight(mg) 
Avg ±S.D
Thickness 
(mm) Avg 
±S.D
Hardness 
kg/cm2Avg±
S.D
Friability 
(%w/w)
Diameter 
(mm)
Drug Content 
uniformity 
(%)
F1 472.3±0.862 4.12±0.11 6.66±0.378 0.829±0.03 11 97.18±0.35
F2 470.1±0.340 4.13±0.08 6.76±0.251 0.853±0.02 11 98.39±0.34
F3 483.5 ±0.055 4.20±0.12 6.79±0.264 0.826±0.13 11 98.39±0.34
F4 482.5 ±0.068 4.18±0.13 6.62±0.458 0.895±0.12 11 98.19±0.34
F5 480 ±0.0529 4.16±0.14 6.86±0.378 0.833±0.06 11 97.39±0.34
F6 472.5 ±0.155 4.23±0.11 6.96±0.321 0.826±0.04 11 98.29±0.6
F7 481.5 ±0.570 4.16±0.10 6.92±0.350 0.84±0.03 11 97.19±0.34
F8 485.5 ±0.755 4.25±0.11 7.01±0.251 0.856±0.02 11 98.59±0.35
F9 480 ±0.895 4.29±0.11 7.0±0.251 0.896±0.03 11 97.19±0.34
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5. IN VITRO BUOYANCY DETERMINATION: 
a. Floating Lag Time:
The time taken to emerge on  the surface of the liquid after adding to the dissolution 
medium at pH 1.2 with 50 sec of F8 least Floating lag time when compare to the other 
formulations.
At  0 second At 20 second At 30 second At 40 second
At 45 second At 48 secondAt 50second
Fig. 35.Floating lag time of F8 formulation
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b. Total floating time:The time taken by the tablet to float constantly on the surface 
of the gastric fluid at pH 1.2 in 100ml beaker were observed as shown Fig.No.22.
FigNo.22 Total floating time of F8 best formulation
2 hour 4 hour 6 hour
8 hour 9 hour
10 hour 11:30 hour
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6. IN VITRO DRUG RELEASE STUDIES:
In vitrodissolution studies of all the formulations of floating tablets of Nizatidine
were carried out in Acid buffer (0.1 N HCl).The study was performed for 12 hour, and
cumulative drug release was calculated at different timeintervals.
Effects of various ingredients and their concentration on drug release were studied. It 
was observed that the type of polymer influences the drug release pattern. The in vitro
drugrelease was observed that as the concentration of polymer is increased in formulations 
(F1 to F9) the time of drug release was decreased.
The in-vitro drug release profiles for the formulations (F1-F12) were tabulated in 
Table.No.21The plot of cumulative drug release (vs) time (hr) was plotted (F1-F3) and 
depicted as shown in Fig.37
Controlled release profiles were observed in the following order, Tamarind seed 
polysaccharide and HPMC K4M > Tamarind seed polysaccharide > HPMC K4M 
irrespective of the type of polymer.
The in-vitro dug release of F8 (TSP 15% & HPMC 15%) effervescent technique was 
the best formulation (F8) when compare with other formulations. The results as shown in
Table. No.21, Fig.No.
Among all the formulations, F8  (Tamarind seed polysaccharide - 15 % & HPMC 
K4M - 15%) had the best formulation on the basis of in vitrodrug release, floating lag 
time, total floating time and swelling index. It showed maximum drug release in a 
Controlled release manner (98.28% in 12hrs) because the formation of strong viscous gel 
layer that slowed down the rate of diffusion of medium into the tablet.
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Table. No.21:In vitroRelease data of Nizatidine floating tablets
Time 
(Hrs)
Percentage of cumulative release F1 – F9
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 20.28 17.4 18.99 19.12 16.94 18.21 16.42 15.22 14.96 
2 27.52 20.24 17.91 25.12 21.42 23.15 24.63 19.98 21.93 
3 28.64 29.54 26.87 33.92 29.54 33.12 32.84 23.16 30.24 
4 35.97 37.95 35.83 46.23 31.54 37.45 41.05 37.93 42.65 
5 42.63 49.42 40.79 55.12 38.54 42.15 49.27 48.69 55.12 
6 56.29 60.23 53.74 59.22 46.15 55.72 56.15 52.13 62.82 
7 62.94 68.57 62.70 67.42 52.19 61.21 65.69 58.92 67.31 
8 68.26 75.42 71.66 79.12 58.49 66.15 73.90 64.52 73.75 
9 77.64 82.24 80.62 83.52 78.21 70.43 82.29 71.57 78.24 
10 94.12 88.5 89.57 96.99 80.23 78.12 94.11 85.94 82.92 
11 94.12 93.12 91.53 96.99 85.29 87.65 94.11 90.41 90.87 
12 94.12 96.21 95.21 96.99 96.21 95.92 94.11 98.28 95.25 
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Fig.No.37.In vitroRelease data of Nizatidine floating tablets F1 – F3
Fig.No.38.In vitroRelease data of Nizatidine floating tablets F4 – F6
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Fig.No.39.In vitroRelease data of Nizatidine floating tablets F7 - F9
Fig.No.40.ComparativesIn vitroRelease data of Nizatidinefloating tablets F1 – F9
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7. IN VITRO RELEASE KINETICSSTUDIES:
TheIn vitro release kineticsstudies were Studies done by using software “DD 
Solver”. The release data (1-12hrs) wasanalyzed as per Zero order, First order, Higuchi’s 
and Peppa’s equation models to know the pattern of drug release and mechanism of drug 
release from the tablet.
Korsmeyer Peppa’s model was found to be the best fitted in all dissolution profile 
having higher correlation coefficient (R2 value). The values of n (diffusion exponent) 
were estimated by linear regression of log cumulative % drug release Vs log time (t) of 
different formulations. The ‘n’ value could be used to characterize different release 
mechanisms as follows,
Table .No.22:Characterize different release mechanisms
S. No. Diffusion exponent value (n) Drug release mechanism
1 < 0.5 Fickian release
2 0.5 to 1.00 Non-Fickian transport
3 1.00 Case II transport
4 > 1.00 Super case II transport
The ‘n’ value of Koresmeyer-Peppas model of all formulations was between 0.929 to 
0.998. The R2 value of best formulation F8 was 0.998. Therefore, the most probable 
mechanism that the release patterns of all formulations followed was Non-fickian 
diffusion.
The drug release mechanism was controlled by both diffusion as well as polymer 
relaxation process. The rate of drug permeation out of the matrix was supposed to be 
proportional to the rate of solvent entry and broadening of the diffusion path length due to 
swelling of the matrix as a result of polymer hydration and subsequent strand relaxation.
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The kinetic studies of all the formulations showed that the Zero order plots were 
fairly linear as indicated by their high regression values compared to Zero order plots. 
Therefore it was as certained that drug release from the all formulations followed Zero 
order kinetics (0.991 to 0.997). Formulation F4 showed the closest linearity to unity (r2= 
0.996). The regression co efficient value (r2) and ‘n’ values of all batches (F1 to F9) were 
depicted in the release kinetics of data of all formulations were showed in Table. No, 
Fig.No.
Table. No.23.In vitrokinetic model for the floating tablet of  Nizatidine (F1-F9)
Formulations Zero 
order
First 
order
Higuchi 
model
Korsmeryer -
peppa's model
r2 r2 r2 r2 n
F1 0.9881 0.9255 0.8894 0.9722 0.867 
F2 0.9915 0.9517 0.9181 0.9913 0.806
F3 0.9929 0.9271 0.8862 0.9865 0.890
F4 0.9941 0.9570 0.9271 0.9931 0.799
F5 0.9911 0.9158 0.8709 0.9795 0.829
F6 0.9936 0.9564 0.9281 0.9913 0.783
F7 0.9971 0.9546 0.9131 0.9904 0.850
F8 0.9952 0.9357 0.8911 0.9950 0.890
F9 0.9865 0.9745 0.9402 0.9919 0.740
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Fig  41.In the comparative kinetic model for the  Formulation F8 is best fit  to Zero 
order kinetics
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Fig. No. 42. In the comparative kinetic model for the  Formulation F8 is best fit  to 
Korsmeryer -peppa's model kinetics
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Table. No.24.Comparative kinetic model for the Formulation F8 is best fit to
Korsmeryer -peppa's model kinetics
Formulation 
code
Zero order First 
order
Higuchi 
model
Korsmeryer -peppa's 
model
r2 r2 r2 r2 n
F8 0.9951 0.9747 0.8911 0.9909 0.8898
8. SELECTION OF BESTFORMULATION:
From the above results, F4 was selected the best formulation based on following 
character,
i. Floatinglag time : 50 seconds.
ii. Totalfloatingtime : up to 12hrs.
iii. Swellingindex : 65.57 % (8hrs).
iv. In-vitro releaseprofile : 98.28% (12hrs).
v. In-vitroreleasekinetics : Zero order kinetics (r2=0.996).
9. IN-VIVO X-RAY STUDIES :
In vivoX-ray for optimized formulation:
∑ X-ray studies were conducted to find out the gastric retention of tablet.
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9. IN-VIVO X-RAY STUDIES :
In vivo X-ray for optimized formulation:
∑ X-ray studies were conducted to find out the gastric retention of tablet.
2nd hour 4th hour
8th hour 9 th hour
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10 th hour 12 th hour
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Fig.No.43.In-Vivo X-Ray Studies of Floating Tablet
Of Nizatidine (Best FormulationF8)
10. EVALUATION OF ACCELERATED STABILITY STUDIES BEST 
FORMULATION (F8)
Stability studies were carried out by using selected formulation i.e. F8. The 
formulation is kept in accelerated stability condition atF temperature 40˚C/75% relative 
humidity for a period of 2 months as per International Conference on Harmonization 
guidelines.
The samples were withdrawn after 60 days intervals and evaluation was carried out 
for appearance, thickness, hardness, buoyancy lag time, drug content and In-vitro release 
studies (60days)
Table.No. 25.Evaluation of nizatidine floating tablets for best formulation (F8)
Formulation Parameters Initial 60days
Average weight (mg) 498.46 498.44
Thickness (mg) 4.39 4.38
Hardness (kg/cm2) 7.24 7.16
Diameter   (mm) 11 11
Floating lag Time(sec) 14sec 15sec
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Swelling Index (8 Hours) 
(%)
64.21 64.20
Table. No.26.In vitro% drug Release of Nizatidine (F8) after 2 months stability 
studies
S.No Time (hrs) Cumulative % Drug Released ± SD at 
40±2⁰C/75±5%RH
1st Day 60th Day
1 0 0 0
2 1 15.22 ±1.2 14.20 ±1.3
3 2 19.98 ±1.4 17.90 ±1.8
4 3 23.16±1.3 22.14±1.9
5 4 37.93 ±1.9 36.91±1.9
6 5 48.69 ±2.0 48.68±1.6
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Fig.  44.In vitro% drug Release of Nizatidine (F8) after 2 months stability studies
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In vitro % drug Release of Nizatidine (F8) after 2 
months stability studies
Initial
Time
After 60
days
7 6 52.13 ±1.5 52.09 ±1.7
8 7 58.92 ±1.2 57.88 ±1.2
9 8 64.52 ±1.6 62.49 ±1.8
10 9 71.57 ±1.7 73.51 ±1.4
11 10 85.94 ±1.8 83.89 ±1.8
12 11 90.41 ±1.7 89.40 ±1.9
13 12 98.28 ±1.9 96.27 ±2.0
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1. Drug delivery through the numerous gastroretentive approaches has opened a new horizon 
for effective way of increasing patient compliance and increasing bioavailability of variety 
of drugs through oral rout. Many approaches with use of different polymers and other 
constituents can produce different range of gastroretentive systems. Especially the floating 
drug delivery system is the most widely used in gastroretentive dosage forms. However a 
lot of work is still needed to be done to overcome the different physiological and 
pharmaceutical barriers to develop the more effective gastroretentive dosage forms. 
2. Nizatidine floating tablets were successfully prepared with hydrophilic polymers like 
HPMC K4M and Tamarind seed polysaccharide. 
3. All formulations were evaluated for Compressibility Index, Angle of repose and Hausner 
ratio. The results indicated that the final blend had good flow and suited for direct 
compression technique. 
4. From the pre-formulation studies for drug excipient compatibility it was observed that 
Nizatidine, doesn’t show any  physical or chemical incompatibility between the drug and 
other excipients. 
5. All formulations were tested for post compression parameters like hardness, thickness, 
weight variation, friability and drug content. All estimated parameters were found to be 
within the limits. This indicated that all the prepared formulations were good 
6. All formulations were tested for buoyancy properties like floating lag time & total floating 
time. Almost all the formulations showed satisfactory results. 
7. All formulations were tested for in vitro drug release. The optimized formulations among 
HPMC K4M and Tamarind seed polysaccharide are F8. It contains combination of 
polymer with tamarind seed polysaccharide and HPMC K4M (1:1)ratio which  exhibit 
least floating lag time in 50 sec and with maximum rate of drug release of 98.28% So, this 
formulation was considered to  be the optimized formulation. 
8. Comparitively kinetic model obtained for the floating tablet of nizatidine best formulation 
F8 and for other formulation are r2 in Zero order kinetics and mechanism is fit to 
Kormeyer –Peppa’s model. 
9. The F8 formulation was chosen as the best formulation among all the other formulations. 
So stability studies are performed after one month also the formulation is stable. 
10. Use of Tamarind seed polysaccharides enhanced the floating lag time, maintained the 
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Controlled release of drugs. 
 
CONCLUSION 
 
Department of pharmaceutics, KMCH college of Pharmacetics, Coimbatore Page 90 
 
CONCLUSION 
 
It can be concluded that the combination of tamarind seed polysaccharide and HPMC in ratio 
of (1:1) can be used to develop controlled release floating tablets of Nizatidine by 
incorporating sodium bicarbonate and citric acid for gas generation. However, clinical 
experiment on the human should be concluded with optimized formulation F8 in order to 
correlate in vivo performance with its in vitro behaviour. 
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